New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsorship, 57992-58016 [2021-22604]
Download as PDF
57992
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
for a ‘‘significant regulatory action’’ as
specified in Executive Order 12866.
Paperwork Reduction Act
There is no new collection of
information required in this document;
therefore, the provisions of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3507) are inapplicable.
Dated: October 15, 2021.
Robert F. Altneu,
Director, Regulations & Disclosure Law
Division, Regulations & Rulings, Office of
Trade, U.S. Customs and Border Protection.
BILLING CODE 9111–14–P
I. Approvals
Signing Authority
This document is limited to a
technical correction of CBP regulations.
Accordingly, it is being signed under
the authority of 19 CFR 0.1(b). Acting
Commissioner Troy A. Miller, having
reviewed and approved this document,
is delegating the authority to
electronically sign this document to
Robert F. Altneu, who is the Director of
the Regulations and Disclosure Law
Division for CBP, for purposes of
publication in the Federal Register.
List of Subjects in 19 CFR Part 122
Air carriers, Aircraft, Airports,
Customs duties and inspection, Freight.
HHS.
PART 122—AIR COMMERCE
REGULATIONS
1. The general authority citation for
part 122 continues to read as follows:
■
Authority: 5 U.S.C. 301; 19 U.S.C. 58b, 66,
1415, 1431, 1433, 1436, 1448, 1459, 1590,
1594, 1623, 1624, 1644, 1644a, 2071 note.
*
*
§ 122.15
*
*
*
[Amended]
2. In § 122.15, amend the table in
paragraph (b) by removing the entry for
‘‘Monroe, North Carolina’’.
■
George K. Haibel, Center for Veterinary
Medicine (HFV–6), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–402–5689,
george.haibel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2021–22880 Filed 10–19–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Amendments to Regulations
Part 122, of title 19 of the Code of
Federal Regulations (19 CFR part 122) is
amended as set forth below:
FOR FURTHER INFORMATION CONTACT:
Food and Drug Administration
21 CFR Parts 510, 516, 520, 522, 526,
556 and 558
[Docket No. FDA–2021–N–0002]
New Animal Drugs; Approval of New
Animal Drug Applications; Changes of
Sponsorship
AGENCY:
Food and Drug Administration,
Final rule; technical
amendments.
ACTION:
The Food and Drug
Administration (FDA or we) is
amending the animal drug regulations to
reflect application-related actions for
new animal drug applications (NADAs),
abbreviated new animal drug
applications (ANADAs), and
conditional new animal drug
applications (cNADAs) during January,
February, and March 2021. FDA is
informing the public of the availability
of summaries of the basis of approval
and of environmental review
documents, where applicable. The
animal drug regulations are also being
amended to improve the accuracy and
readability of the regulations.
DATES: This rule is effective October 20,
2021.
SUMMARY:
FDA is amending the animal drug
regulations to reflect approval actions
for NADAs, ANADAs, and conditional
approval actions for cNADAs during
January, February, and March 2021, as
listed in table 1. In addition, FDA is
informing the public of the availability,
where applicable, of documentation of
environmental review required under
the National Environmental Policy Act
(NEPA) and, for actions requiring
review of safety or effectiveness data,
summaries of the basis of approval (FOI
Summaries) under the Freedom of
Information Act (FOIA). These public
documents may be seen in the office of
the Dockets Management Staff (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852, between 9 a.m. and 4 p.m.,
Monday through Friday, 240–402–7500.
Persons with access to the internet may
obtain these documents at the CVM
FOIA Electronic Reading Room: https://
www.fda.gov/about-fda/centerveterinary-medicine/cvm-foiaelectronic-reading-room. Marketing
exclusivity and patent information may
be accessed in FDA’s publication,
Approved Animal Drug Products Online
(Green Book) at: https://www.fda.gov/
animal-veterinary/products/approvedanimal-drug-products-green-book.
FDA has verified the website
addresses as of the date this document
publishes in the Federal Register, but
websites are subject to change over time.
TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAS AND ANADAS APPROVED DURING JANUARY, FEBRUARY, AND MARCH
2021
lotter on DSK11XQN23PROD with RULES1
Approval date
File No.
Sponsor
Product name
Species
Effect of the action
Public
documents
Supplemental approval for the addition
of Mycoplasma hyopneumoniae to
the list of pathogens for the control
of swine respiratory disease indication.
Conditional approval for the treatment
of lymphoma in dogs.
FOI Summary.
January 8, 2021 .........
141–336
ECO LLC, 344 Nassau
St., Princeton, NJ
08540.
AIVLOSIN (62.5% w/w
tylvalosin as tylvalosin
tartrate) Water Soluble
Granules.
Swine .........
January 11, 2021 .......
141–526
LAVERDIA–CA1
(verdinexor tablets).
Dogs ...........
January 12, 2021 .......
200–675
Original approval as a generic copy of
NADA 141–225.
FOI Summary.
200–676
Ractopamine hydrochloride and monensin
Type B and Type C
medicated feeds.
Ractopamine hydrochloride, monensin,
and tylosin phosphate
Type B and Type C
medicated feeds.
Cattle ..........
January 12, 2021 .......
Anivive Lifesciences, Inc.,
3250 Airflite Way, Suite
400, Long Beach, CA
90807.
Huvepharma EOOD, 5th
Floor, 3A Nikolay
Haytov Str., 1113
Sofia, Bulgaria.
Do ....................................
Cattle ..........
Original approval as a generic copy of
NADA 141–224.
FOI Summary.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00008
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
FOI Summary.
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
57993
TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAS AND ANADAS APPROVED DURING JANUARY, FEBRUARY, AND MARCH
2021—Continued
lotter on DSK11XQN23PROD with RULES1
Approval date
File No.
Sponsor
Product name
Species
Effect of the action
Public
documents
Ractopamine hydrochloride, monensin,
and melengestrol acetate Type C medicated
feeds.
Ractopamine hydrochloride, monensin,
tylosin phosphate, and
melengestrol acetate
Type C medicated
feeds.
KBROVET–CA1 (potassium bromide chewable
tablets) Chewable Tablet.
THYROKARE
(levothyroxine sodium
tablets).
Melengestrol acetate and
monensin Type C
medicated feeds.
Cattle ..........
Original approval as a generic copy of
NADA 141–234.
FOI Summary.
Cattle ..........
Original approval as a generic copy of
NADA 141–233.
FOI Summary.
Dogs ...........
Conditional approval for the control of
seizures associated with idiopathic
epilepsy in dogs.
FOI Summary.
Dogs ...........
Original approval for replacement therapy for diminished thyroid function
in dogs.
Original approval as a generic copy of
NADA 125–476.
FOI Summary.
Ractopamine hydrochloride, monensin,
and melengestrol acetate Type C medicated
feeds.
Melengestrol acetate,
monensin, and tylosin
phosphate Type C
medicated feeds.
Monensin, ractopamine
hydrochloride, tylosin
phosphate, and
melengestrol acetate
Type C medicated
feeds.
SPARMECTIN Plus
Clorsulon (ivermectin
and clorsulon) Injection.
Cattle ..........
Original approval as a generic copy of
NADA 141–234.
FOI Summary.
Cattle ..........
Original approval as a generic copy of
NADA 138–870.
FOI Summary.
Cattle ..........
Original approval as a generic copy of
NADA 141–233.
FOI Summary.
Cattle ..........
Supplemental approval reducing
preslaughter withdrawal period to 21
days.
FOI Summary.
ANIMEC PLUS
(ivermectin and
clorsulon) Injection.
Cattle ..........
Original approval as a generic copy of
NADA 140–833.
FOI Summary.
MACROSYN
(tulathromycin injection)
Injectable Solution.
Cattle ..........
Original approval as a generic copy of
NADA 141–244.
FOI Summary.
INCREXXA
(tulathromycin injection)
Injectable Solution.
PENNITRACIN MD (bacitracin Type A medicated article) and
COBAN (monensin
Type A medicated article) to be used in the
manufacture of Type C
medicated feeds.
Dexmedetomidine Hydrochloride Injection
(dexmedetomidine hydrochloride).
Cattle ..........
Original approval as a generic copy of
NADA 141–244.
FOI Summary.
Turkeys ......
Original approval for the prevention of
coccidiosis caused by Eimeria
adenoeides, E. meleagrimitis and E.
gallopavonis, and for increased rate
of weight gain and improved feed
efficiency in growing turkeys.
FOI Summary.
Dogs and
cats.
Original approval as a generic copy of
NADA 141–267.
FOI Summary.
January 12, 2021 .......
200–677
Do ....................................
January 12, 2021 .......
200–678
Do ....................................
January 14, 2021 .......
141–544
Pegasus Laboratories,
Inc., 8809 Ely Rd.,
Pensacola, FL 32514.
January 15, 2021 .......
141–539
February 1, 2021 ........
200–683
February 1, 2021 ........
200–684
Neogen Corp., 944
Nandino Blvd., Lexington, KY 40511.
Huvepharma EOOD, 5th
Floor, 3A Nikolay
Haytov Str., 1113
Sofia, Bulgaria.
Do ....................................
February 1, 2021 ........
200–685
Do ....................................
February 1, 2021 ........
200–686
Do ....................................
February 8, 2021 ........
200–466
February 16, 2021 ......
200–506
February 18, 2021 ......
200–657
February 18, 2021 ......
200–666
February 26, 2021 ......
141–540
Sparhawk Laboratories,
Inc., 12340 Santa Fe
Trail Dr., Lenexa, KS
66215.
Chanelle Pharmaceuticals Manufacturing
Ltd., Loughrea, County
Galway, Ireland.
Bimeda Animal Health
Ltd., 1B The Herbert
Building, The Park,
Carrickmines, Dublin
18, Ireland.
Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140.
Pharmgate, Inc., 1800 Sir
Tyler Dr., Wilmington,
NC 28405.
March 11, 2021 ..........
200–699
VerDate Sep<11>2014
16:22 Oct 19, 2021
Akorn Animal Health,
Inc., 1925 West Field
Ct., Suite 300, Lake
Forest, IL 60045.
Jkt 256001
PO 00000
Frm 00009
Fmt 4700
Sfmt 4700
Cattle ..........
E:\FR\FM\20OCR1.SGM
20OCR1
FOI Summary.
57994
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAS AND ANADAS APPROVED DURING JANUARY, FEBRUARY, AND MARCH
2021—Continued
Approval date
File No.
Sponsor
Species
Effect of the action
Public
documents
Original approval for increased rate of
weight gain, improved feed efficiency, and suppression of estrus
(heat) in replacement dairy and beef
heifers, or growing beef heifers fed
in confinement for slaughter receiving medicated feed containing chlortetracycline for the treatment of bacterial enteritis or pneumonia, control
of bacterial pneumonia associated
with shipping fever complex, reduction of incidence of liver abscesses,
and control of active infection of
anaplasmosis.
Original approval for suppression of
estrus (heat) in replacement dairy
and beef heifers, or growing beef
heifers fed in confinement for
slaughter receiving medicated feed
containing chlortetracycline for the
treatment of bacterial enteritis or
pneumonia, control of bacterial
pneumonia associated with shipping
fever complex, or control of active
infection of anaplasmosis; and
lasalocid for control of coccidiosis,
increased rate of weight gain, and
improved feed efficiency.
Original approval as a generic copy of
NADA 140–269.
FOI Summary.
March 15, 2021 ..........
141–530
Zoetis Inc., 333 Portage
St., Kalamazoo, MI
49007.
MGA (melengestrol acetate Type A medicated
article) and AUREOMYCIN (chlortetracycline Type A medicated article) to be
used in the manufacture of Type C medicated feeds.
Cattle ..........
March 19, 2021 ..........
141–531
Do ....................................
MGA (melengestrol acetate Type A medicated
article), AUREOMYCIN
(chlortetracycline Type
A medicated article),
and BOVATEC
(lasalocid Type A medicated article) to be
used in the manufacture of Type C medicated feeds.
Cattle ..........
March 22, 2021 ..........
200–625
KETOMED (ketoprofen)
Sterile Solution.
Horses ........
March 24, 2021 ..........
132–872
Bimeda Animal Health
Ltd., 1B The Herbert
Building, The Park,
Carrickmines, Dublin
18, Ireland.
Intervet, Inc., 2 Giralda
Farms, Madison, NJ
07940.
SAFE–GUARD
(fenbendazole) Paste
10%.
Cattle ..........
II. Changes of Sponsor
FDA that they have transferred
ownership of, and all rights and interest
The sponsors of the following
approved applications have informed
File No.
Product name
141–175 ...........
CAPSTAR (nitenpyram) Tablets .....
Elanco US Inc., 2500 Innovation
Way, Greenfield, IN 46140.
141–120 ...........
CLOMICALM (clomipramine hydrochloride) Tablets.
ITRAFUNGOL (itraconazole oral
solution).
GO–DRY (penicillin G procaine)
Intramammary Infusion.
Do ...................................................
Ampicillin Sodium Powder for Injection.
HAN–PEN (penicillin G potassium)
Soluble Powder.
Chlortetracycline (chlortetracycline
hydrochloride) Soluble Powder.
141–474 ...........
065–081 ...........
200–335 ...........
200–372 ...........
065–071 ...........
lotter on DSK11XQN23PROD with RULES1
Product name
065–440 ...........
200–441 ...........
200–528 ...........
VerDate Sep<11>2014
Jkt 256001
PO 00000
FOI Summary.
FOI Summary.
in, these applications to another
sponsor:
Transferring sponsor
CHLORONEX (chlortetracycline hydrochloride) Soluble Powder.
A-MYCIN (chlortetracycline hydrochloride) Soluble Powder.
SAVALAN 60 (salinomycin sodium)
Type A medicated article.
16:22 Oct 19, 2021
Supplemental approval providing for
tolerances, a tissue withdrawal period, and a milk discard time in accordance with a repartitioning of the
acceptable daily intake; and the addition of indications for fourth-stage
larvae of certain endoparasites.
FOI Summary.
New sponsor
21 CFR
section
Sergeant’s Pet Care Products, Inc.,
10077 S 134th St., Omaha, NE
68138.
Virbac AH, Inc., P.O. Box 162059,
Fort Worth, TX 76161.
Do ...................................................
520.1510.
526.1696.
Do ...................................................
HQ Specialty Pharma Corp., 120
Rte. 17 North, Suite 130,
Paramus, NJ 07652.
Do ...................................................
Do ...................................................
Do ...................................................
520.1696a.
Huvepharma EOOD, 5th Floor, 3A
Nikolay Haytov Str., 1113 Sofia,
Bulgaria.
Do ...................................................
Pharmgate Inc., 1800 Sir Tyler Dr.,
Wilmington, NC 28405.
520.441.
Do ...................................................
Do.
Do ...................................................
Do ...................................................
Do.
Pharmgate Inc., 1800 Sir Tyler Dr.,
Wilmington, NC 28405.
Huvepharma EOOD, 5th Floor, 3A
Nikolay Haytov Str., 1113 Sofia,
Bulgaria.
558.550.
Do ...................................................
G. C. Hanford Mfg. Co., P.O. Box
1017, Syracuse, NY 13201.
Frm 00010
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
520.455.
520.1189.
522.90c.
57995
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
21 CFR
section
File No.
Product name
Transferring sponsor
New sponsor
200–237 ...........
Isoflurane, U.S.P .............................
Piramal Enterprises Ltd., Ananta,
Agastya Corporate Park, Opp
Fire Brigade, Kamani Junction,
LBS Mag Kurla (West), Mumbai,
400070, India.
Piramal Pharma Ltd., Ground Floor,
Piramal Ananta, Agastya Corporate Park, Mumbai,
Maharashtra, 400070, India.
Following these changes of
sponsorship, G. C. Hanford
Manufacturing Co. and Piramal
Enterprises Ltd. are no longer the
sponsor of an approved application.
Accordingly, the regulations in 21 CFR
510.600(c) are being amended to reflect
these changes.
III. Technical Amendments
FDA is making the following
amendments to improve the accuracy,
consistency, and readability of the
animal drug regulations:
• 21 CFR 510.600 is amended by
revising the entries for Cronus Pharma
Specialities India Private Ltd. to reflect
the correct address for the firm.
• 21 CFR 520.2090 is amended to
reflect the current approved indications
for use for sarolaner, moxidectin, and
pyrantel tablets.
• 21 CFR 522.970 is amended to
reflect the approved species for a
flunixin injectable solution.
• 21 CFR 558.76 for use of bacitracin
methylenedisalicylate in medicated feed
is amended to reflect a current tabular
format organized by species.
• 21 CFR 558.128 is amended to
reflect sponsors of combination
medicated feeds containing
chlortetracycline for which there is no
preslaughter withdrawal period.
• 21 CFR 558.355 for use of monensin
in medicated feeds is amended to reflect
the sponsor of an approved generic
product and to remove a redundant
condition of use.
IV. Legal Authority
This final rule is issued under section
512(i) of the Federal Food, Drug, and
Cosmetic Act (FD&C Act) (21 U.S.C.
360b(i)), which requires Federal
Register publication of ‘‘notice[s] . . .
effective as a regulation,’’ of the
conditions of use of approved new
animal drugs. This rule sets forth
technical amendments to the regulations
to codify recent actions on approved
new animal drug applications and
corrections to improve the accuracy of
the regulations, and as such does not
impose any burden on regulated
entities.
Although denominated a rule
pursuant to the FD&C Act, this
document does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a ‘‘rule of particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808. Likewise, this is not a
rule subject to Executive Order 12866,
which defines a rule as ‘‘an agency
statement of general applicability and
future effect, which the agency intends
to have the force and effect of law, that
is designed to implement, interpret, or
prescribe law or policy or to describe
the procedure or practice requirements
of an agency.’’
List of Subjects
21 CFR Part 510
Administrative practice and
procedure, Animal drugs, Labeling,
Reporting and recordkeeping
requirements.
21 CFR Part 516
Administrative practice and
procedure, Animal drugs, Confidential
business information, Reporting and
recordkeeping requirements.
21 CFR Parts 520, 522, and 526
Animal drugs.
21 CFR Part 556
Animal drugs, Food.
21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food,
Drug, and Cosmetic Act, 21 CFR parts
510, 516, 520, 522, 526, 556, and 558 are
amended as follows:
PART 510—NEW ANIMAL DRUGS
1. The authority citation for part 510
continues to read as follows:
■
Authority: 21 U.S.C. 321, 331, 351, 352,
353, 360b, 371, 379e.
2. In § 510.600:
a. In the table in paragraph (c)(1):
■ i. Add in alphabetical order an entry
for ‘‘Anivive Lifesciences, Inc.’’;
■ ii. Revise the entry for ‘‘Cronus
Pharma Specialities India Private Ltd.’’;
■ iii. Remove the entries for ‘‘G. C.
Hanford Manufacturing Co.’’ and
‘‘Piramal Enterprises Ltd.’’; and
■ iv. Add in alphabetical order an entry
for ‘‘Piramal Pharma Ltd.’’; and
■ b. In the table in paragraph (c)(2):
■ i. Remove the entry for ‘‘010515’’;
■ ii. Revise the entries for ‘‘065085’’ and
‘‘069043’’; and
■ iii. Add in numerical order an entry
for ‘‘086121’’.
The revisions and additions read as
follows:
■
■
§ 510.600 Names, addresses, and drug
labeler codes of sponsors of approved
applications.
*
*
*
(c) * * *
(1) * * *
*
*
Drug labeler
code
Firm name and address
lotter on DSK11XQN23PROD with RULES1
N/A.
*
*
*
*
*
*
Anivive Lifesciences, Inc., 3250 Airflite Way, Suite 400, Long Beach, CA 90807 .............................................................................
*
*
*
*
*
*
*
Cronus Pharma Specialities India Private Ltd., Sy No–99/1, M/s GMR Hyderabad Aviation SEZ Ltd., Mamidipalli Village,
Shamshabad Mandal, Ranga Reddy, Hyderabad, Telangana, 501218, India ................................................................................
*
*
*
*
*
*
*
Piramal Pharma Ltd., Ground Floor, Piramal Ananta, Agastya Corporate Park, Mumbai, Maharashtra, 400070, India ...................
.
*
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00011
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
086121
069043
065085
57996
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Drug labeler
code
Firm name and address
*
*
*
*
*
*
*
(2) * * *
Drug labeler
code
Firm name and address
*
065085 ............
*
*
*
*
*
*
Piramal Pharma Ltd., Ground Floor, Piramal Ananta, Agastya Corporate Park, Mumbai, Maharashtra, 400070, India
*
069043 ............
*
*
*
*
*
*
Cronus Pharma Specialities India Private Ltd., Sy No–99/1, M/s GMR Hyderabad Aviation SEZ Ltd., Mamidipalli Village,
Shamshabad Mandal, Ranga Reddy, Hyderabad, Telangana, 501218, India
*
086121 ............
*
*
*
*
Anivive Lifesciences, Inc., 3250 Airflite Way, Suite 400, Long Beach, CA 90807
*
*
*
PART 516—NEW ANIMAL DRUGS FOR
MINOR USE AND MINOR SPECIES
3. The authority citation for part 516
continues to read as follows:
■
Authority: 21 U.S.C. 360ccc, 360ccc–2,
371.
4. Add § 516.1858 to subpart E to read
as follows:
■
§ 516.1858
Potassium bromide.
(a) Specifications. Each chewable
tablet contains 250 or 500 milligrams
(mg) potassium bromide.
(b) Sponsor. See No. 055246 in
§ 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount.
Administer 25 to 68 mg per kilogram (11
to 31 mg per pound) of body weight
once daily. The dosage can be divided
and should be adjusted to clinical
response.
(2) Indications for use. For the control
of seizures associated with idiopathic
epilepsy in dogs.
(3) Limitations. Federal law restricts
this drug to use by or on the order of
a licensed veterinarian. It is a violation
of Federal law to use this product other
than as directed in the labeling.
■ 5. Add § 516.2980 to subpart E to read
as follows:
lotter on DSK11XQN23PROD with RULES1
§ 516.2980
Verdinexor.
(a) Specifications. Each tablet
contains 2.5, 10, or 50 milligrams (mg)
verdinexor.
(b) Sponsor. See No. 086121 in
§ 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount.
Administer verdinexor tablets orally at
an initial dose of 1.25 mg per kilogram
(mg/kg) of body weight twice per week
with at least 72 hours between doses. If
tolerated after 2 weeks, increase the
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
*
*
dose to 1.5 mg/kg twice per week with
at least 72 hours between doses.
(2) Indications for use. For the
treatment of lymphoma in dogs.
(3) Limitations. Federal law restricts
this drug to use by or on the order of
a licensed veterinarian. It is a violation
of Federal law to use this product other
than as directed in the labeling.
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
6. The authority citation for part 520
continues to read as follows:
■
Authority: 21 U.S.C. 360b.
7. In § 520.441, revise paragraph (b)(1)
to read as follows:
■
§ 520.441
Chlortetracycline powder.
*
*
*
*
*
(b) * * *
(1) Nos. 000010, 054771, and 069254
for use as in paragraph (d) of this
section.
*
*
*
*
*
■ 8. In § 520.455, revise the section
heading and paragraph (b) to read as
follows:
§ 520. 455
Clomipramine.
*
*
*
*
*
(b) Sponsors. See Nos. 051311 and
086039 in § 510.600(c) of this chapter.
*
*
*
*
*
■ 9. In § 520.905c, revise paragraph
(e)(2) to read as follows:
§ 520.905c
Fenbendazole paste.
*
*
*
*
*
(e) * * *
(2) Beef and dairy cattle—(i) Amount.
Administer orally 2.3 mg/lb (5 mg/kg)
body weight.
PO 00000
Frm 00012
Fmt 4700
Sfmt 4700
*
*
*
*
(ii) Indications for use. For the
treatment and control of: Lungworms:
Adult (Dictyocaulus viviparus);
Stomach worms: Adult brown stomach
worms (Ostertagia ostertagi), adult and
fourth-stage larvae barberpole worms
(Haemonchus contortus), fourth-stage
larvae barberpole worms (H. placei), and
adult and fourth-stage larvae small
stomach worms (Trichostrongylus axei);
Intestinal worms (adult and fourth-stage
larvae): Hookworms (Bunostomum
phlebotomum), thread-necked intestinal
worms (Nematodirus helvetianus), small
intestinal worms (Cooperia punctata
and C. oncophora), bankrupt worms
(Trichostrongylus colubriformis), and
nodular worms (Oesophagostomum
radiatum).
(iii) Limitations. Milk taken during
treatment and for 96 hours after the last
treatment must not be used for human
consumption. Cattle must not be
slaughtered for human consumption
within 8 days following last treatment
with this drug product. Not for use in
beef calves less than 2 months of age,
dairy calves, and veal calves. A
withdrawal period has not been
established for this product in
preruminating calves.
■ 10. In § 520.1189, revise paragraph (b)
to read as follows:
§ 520.1189
Itraconazole.
*
*
*
*
*
(b) Sponsor. See No. 051311 in
§ 510.600(c) of this chapter.
*
*
*
*
*
■ 11. In § 520.1248, revise paragraphs
(b) and (c)(1) to read as follows:
§ 520.1248
Levothyroxine.
*
*
E:\FR\FM\20OCR1.SGM
*
20OCR1
*
*
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
(b) Sponsors. See Nos. 059051 and
061690 in § 510.600(c) of this chapter.
(c) * * *
(1) Amount. Administer by mouth as
follows:
(i) No. 061690: 0.1 mg/10 pounds (lb)
body weight (0.022 mg/kilogram (kg)) as
a single dose every 24 hours or as a
divided dose every 12 hours.
(ii) No. 059051: 0.1 mg/10 lb (0.01
mg/lb, 0.022 mg/kg) body weight twice
daily.
*
*
*
*
*
■ 12. In § 520.1510, revise paragraph
(b)(1) to read as follows:
(2) Indications for use. For control of
porcine proliferative enteropathy (PPE)
associated with Lawsonia intracellularis
infection in groups of swine intended
for slaughter in buildings experiencing
an outbreak of PPE; and for control of
swine respiratory disease (SRD)
associated with Bordetella
bronchiseptica, Haemophilus parasuis,
Pasteurella multocida, Streptococcus
suis, and Mycoplasma hyopneumoniae
in groups of swine intended for
slaughter in buildings experiencing an
outbreak of SRD.
*
*
*
*
*
§ 520. 1510
PART 522—IMPLANTATION OR
INJECTABLE DOSAGE FORM NEW
ANIMAL DRUGS
Nitenpyram.
*
*
*
*
*
(b) * * *
(1) No. 021091 for use as in
paragraphs (d)(1)(i)(A), (d)(1)(ii)(A), and
(d)(2) of this section.
*
*
*
*
*
■ 13. In § 520.1696a, revise paragraph
(b) to read as follows:
§ 520.1696a
Penicillin G powder.
Authority: 21 U.S.C. 360b.
17. In § 522.90c, revise paragraph (b)
to read as follows:
■
§ 522.90c
*
*
*
*
*
(b) Sponsors. See Nos. 016592,
042791, 054771, 061133, and 076475 in
§ 510.600(c) of this chapter.
*
*
*
*
*
■ 14. In § 520.2090, revise paragraph
(c)(2) to read as follows:
*
§ 520.2090
pyrantel.
*
Sarolaner, moxidectin, and
*
lotter on DSK11XQN23PROD with RULES1
16. The authority citation for part 522
continues to read as follows:
■
*
*
*
*
(c) * * *
(2) Indications for use. For the
prevention of heartworm disease caused
by Dirofilaria immitis and for the
treatment and control of roundworm
(immature adult and adult Toxocara
canis and adult Toxascaris leonina) and
adult hookworm (Ancylostoma caninum
and Uncinaria stenocephala) infections.
Kills adult fleas (Ctenocephalides felis)
and is indicated for the treatment and
prevention of flea infestations, and the
treatment and control of tick
infestations with Amblyomma
americanum (lone star tick),
Amblyomma maculatum (Gulf Coast
tick), Dermacentor variabilis (American
dog tick), Ixodes scapularis (blacklegged tick), and Rhipicephalus
sanguineus (brown dog tick) for 1
month in dogs and puppies 8 weeks of
age and older, and weighing 2.8 pounds
or greater.
*
*
*
*
*
■ 15. In § 520.2645, revise paragraph
(d)(2) to read as follows:
§ 520.2645
*
Tylvalosin.
*
*
(d) * * *
VerDate Sep<11>2014
*
*
16:22 Oct 19, 2021
Jkt 256001
Ampicillin sodium.
*
*
*
*
(b) See Nos. 042791 and 054771 in
§ 510.600(c) of this chapter.
*
*
*
*
*
■ 18. In § 522.558, revise paragraphs
(b)(1) and to read as follows:
§ 522.558
Dexmedetomidine.
*
*
*
*
(b) * * *
(1) Nos. 026637 and 059399 for use of
product described in paragraph (a)(2) of
this section.
*
*
*
*
*
■ 19. In § 522.970, revise paragraph
(b)(1) and add paragraph (b)(3) to read
as follows:
§ 522.970
Flunixin.
*
*
*
*
*
(b) * * *
(1) See Nos. 000061, 055529, 058198,
and 061133 for use as in paragraph (e)
of this section.
*
*
*
*
*
(3) See No. 016592 for use as in
paragraphs (e)(1) and (e)(2) of this
section.
*
*
*
*
*
■ 20. In § 522.1193, revise paragraphs
(b) and (e)(2) and (3) to read as follows:
§ 522.1193
Ivermectin and clorsulon.
*
*
*
*
*
(b) Sponsors. See Nos. 000010,
055529, 058005, 061133, and 061651 in
§ 510.600(c) of this chapter.
*
*
*
*
*
(e) * * *
(2) Indications for use. For the
treatment and control of gastrointestinal
PO 00000
Frm 00013
Fmt 4700
Sfmt 4700
57997
nematodes (adults and fourth-stage
larvae) (Haemonchus placei, Ostertagia
ostertagi (including inhibited larvae), O.
lyrata, Trichostrongylus axei, T.
colubriformis, Cooperia oncophora, C.
punctata, C. pectinata,
Oesophagostomum radiatum,
Nematodirus helvetianus (adults only),
N. spathiger (adults only), Bunostomum
phlebotomum; lungworms (adults and
fourth-stage larvae) (Dictyocaulus
viviparus); liver flukes (adults only)
(Fasciola hepatica); cattle grubs
(parasitic stages) (Hypoderma bovis, H.
lineatum); sucking lice (Linognathus
vituli, Haematopinus eurysternus,
Solenopotes capillatus); mange mites
(cattle scab) (Psoroptes ovis (syn. P.
communis var. bovis), Sarcoptes scabiei
var. bovis); and for control of infections
of D. viviparus and O. radiatum for 28
days after treatment; O. ostertagi, T.
axei, and C. punctata for 21 days after
treatment; and H. placei and C.
oncophora for 14 days after treatment.
(3) Limitations. Do not treat cattle
within 21 days of slaughter. Because a
withdrawal time in milk has not been
established, do not use in female dairy
cattle of breeding age. A withdrawal
period has not been established for this
product in preruminating calves. Do not
use in calves to be processed for veal.
■ 21. In § 522.1225, revise paragraph (b)
to read as follows:
§ 522.1225
Ketoprofen.
*
*
*
*
*
(b) Sponsors. See Nos. 054771 and
061133 in § 510.600(c) of this chapter.
*
*
*
*
*
■ 22. In § 522.1696a, revise paragraph
(d)(2)(iii) to read as follows:
§ 522.1696a Penicillin G benzathine and
penicillin G procaine suspension.
*
*
*
*
*
(d) * * *
(2) * * *
(iii) Limitations. Not for use within 30
days of slaughter. For No. 016592: A
withdrawal period has not been
established for this product in preruminating calves. Do not use in calves
to be processed for veal.
■ 23. In § 522.2630, revise paragraphs
(b) and (d)(1)(iii)(A) to read as follows:
§ 522.2630
Tulathromycin.
*
*
*
*
*
(b) Sponsors. See sponsor numbers in
§ 510.600(c) of this chapter.
(1) Nos. 054771, 058198, and 061133
for use of product described in
paragraph (a)(1) as in paragraphs
(d)(1)(i), (d)(1)(ii), (d)(1)(iii)(A), and
(d)(2) of this section.
(2) No. 054771 for use of product
described in paragraph (a)(2) as in
E:\FR\FM\20OCR1.SGM
20OCR1
57998
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
paragraphs (d)(1)(i), (d)(1)(ii)(B),
(d)(1)(iii)(B), and (d)(2) of this section.
*
*
*
*
*
(d) * * *
(1) * * *
(iii) * * *
(A) Cattle intended for human
consumption must not be slaughtered
within 18 days from the last treatment.
This drug is not approved for use in
female dairy cattle 20 months of age or
older, including dry dairy cows. Use in
these cattle may cause drug residues in
milk and/or in calves born to these
cows. Federal law restricts this drug to
use by or on the order of a licensed
veterinarian.
*
*
*
*
*
PART 526—INTRAMAMMARY DOSAGE
FORM NEW ANIMAL DRUGS
24. The authority citation for part 526
continues to read as follows:
■
Authority: 21 U.S.C. 360b.
(b) See Nos. 042791 and 061133 in
§ 510.600(c) of this chapter.
*
*
*
*
*
Authority: 21 U.S.C. 354, 360b, 360ccc,
360ccc–1, 371.
PART 556—TOLERANCES FOR
RESIDUES OF NEW ANIMAL DRUGS
IN FOOD
■
26. The authority citation for part 556
continues to read as follows:
■
Authority: 21 U.S.C. 342, 360b, 371.
27. In § 556.275:
a. Revise paragraph (b)(1)(ii);
b. Remove paragraph (b)(1)(iii); and
c. Remove and reserve paragraphs
(b)(3)(ii), (b)(4)(ii), and (b)(5)(ii).
The revision reads as follows:
■
■
■
■
§ 556.275
Fenbendazole.
*
*
*
*
*
(b) * * *
(1) * * *
(ii) Milk: 0.22 ppm fenbendazole
sulfoxide (marker residue).
*
*
*
*
*
25. In § 526.1696, revise paragraph (b)
to read as follows:
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
§ 526.1696
Penicillin G procaine.
■
*
*
■
*
*
28. The authority citation for part 558
continues to read as follows:
*
29. In § 558.76:
a. Revise paragraphs (a)(1) and (2) and
(d)(1);
■ b. Redesignate paragraph (d)(2) as
paragraph (d)(6); and
■ c. Add new paragraph (d)(2) and
paragraphs (d)(3) through (5).
The revisions and additions read as
follows:
■
§ 558.76
Bacitracin methylenedisalicylate.
(a) * * *
(1) Type A medicated articles
containing feed grade bacitracin
methylenedisalicylate equivalent to 10,
25, 30, 40, 50, 60, or 75 grams bacitracin
per pound.
(2) Type A medicated article
containing feed grade bacitracin
methylenedisalicylate equivalent to 50
grams bacitracin per pound.
*
*
*
*
*
(d) * * *
(1) Chickens—
Bacitracin in
grams per ton
Indications for use
Limitations
(i) 4 to 50 .............
Broiler and replacement chickens: For increased rate
of weight gain and improved feed efficiency.
Laying hens: For increased egg production and improved feed efficiency.
Broiler and replacement chickens: As an aid in the
prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms
susceptible to bacitracin.
Broiler and replacement chickens: As an aid in the
control of necrotic enteritis caused or complicated
by Clostridium spp. or other organisms susceptible
to bacitracin.
Feed continuously as sole ration ................................
Indications for use
Limitations
(ii) 10 to 25 ..........
(iii) 50 ..................
(iv) 100 to 200 .....
Feed continuously as sole ration for the first 7
months of egg production.
Feed continuously as sole ration ................................
Feed continuously as sole ration. Start at first clinical
signs of disease. Vary dosage based on severity of
infection. Administer continuously for 5 to 7 days or
as long as clinical signs persist, then reduce medication to prevention level (50 grams/ton).
Sponsor
054771
069254
054771
054771
054771
(2) Turkeys—
Bacitracin in
grams per ton
(i) 4 to 50 .............
(ii) 200 .................
Growing turkeys: For increased rate of weight gain
and improved feed efficiency.
Growing turkeys: As an aid in the control of transmissible enteritis complicated by organisms susceptible to bacitracin methylenedisalicylate.
Feed continuously as sole ration ................................
Feed continuously as the sole ration ..........................
Sponsor
054771
069254
054771
lotter on DSK11XQN23PROD with RULES1
(3) Swine—
Bacitracin in
grams per ton
(i) 10 to 30 ...........
VerDate Sep<11>2014
Indications for use
Limitations
Growing and finishing swine: For increased rate of
weight gain and improved feed efficiency.
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00014
Fmt 4700
......................................................................................
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
054771
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Bacitracin in
grams per ton
Indications for use
Limitations
(ii) 250 .................
Growing and finishing swine: For control of swine
dysentery (bloody scours) associated with
Brachyspira hyodysenteriae in pigs up to 250 lbs
body weight.
(iii) 250 ................
Pregnant sows: For control of clostridial enteritis
caused by Clostridium perfringens in suckling piglets.
Feed as the sole ration. Feed 250 grams per ton of
complete feed on premises with a history of swine
dysentery, but where signs of the disease have not
yet occurred or following an approved treatment of
the disease condition. Diagnosis should be confirmed by a veterinarian a when results are not satisfactory.
As the sole ration. Feed to sows from 14 days before
through 21 days after farrowing on premises with a
history of clostridial scours. Diagnosis should be
confirmed by a veterinarian when results are not
satisfactory.
57999
Sponsor
054771
054771
(4) Cattle—
Bacitracin
amount
Indications for use
(i) 70 mg per
head per day.
Limitations
Beef steers and heifers fed in confinement for
slaughter: For reduction in the number of liver condemnations due to abscesses.
Beef steers and heifers fed in confinement for
slaughter: For reduction in the number of liver condemnations due to abscesses.
(ii) 250 mg per
head per day.
Sponsor
Administer continuously throughout the feeding period.
054771
069254
Administer continuously for 5 days then discontinue
for subsequent 25 days, repeat the pattern during
the feeding period.
054771
069254
(5) Game birds—
Bacitracin in
grams per ton
Indications for use
Limitations
(i) 4 to 50 .............
Growing pheasants: For increased rate of weight
gain and improved feed efficiency.
Growing quail: For increased rate of weight gain and
improved feed efficiency in quail not over 5 weeks
of age.
Growing quail: For the prevention of ulcerative enteritis in growing quail due to Clostridium colinum
susceptible to bacitracin methylenedisalicylate.
Feed continuously as sole ration ................................
(ii) 5 to 20 ............
(iii) 200 ................
*
*
*
*
§ 558.128
*
30. In § 558.128, revise paragraphs
(d)(4) and (e)(4) to read as follows:
■
lotter on DSK11XQN23PROD with RULES1
Chlortetracycline amount
Feed continuously as sole ration to quail not over 5
weeks of age.
054771
069254
054771
069254
Feed continuously as the sole ration ..........................
054771
Chlortetracycline.
*
*
*
*
*
(d) * * *
(4) Manufacture for use in free-choice
feeds as in paragraph (e)(4)(vi) of this
Combination in grams/
ton
Limitations
........................................
Growing cattle (over 400 lb): For reduction of liver condemnation due
to liver abscesses.
(ii) 5.83 to 14 g/ton to
provide 70 mg/head/
day.
Melengestrol acetate,
0.25 to 2 g/ton to provide 0.25 to 0.5 mg
melengestrol acetate
per head per day.
Growing beef heifers fed in confinement for slaughter (over 400 lb):
For reduction of the incidence of
liver abscesses, increased rate of
weight gain, improved feed efficiency, and suppression of estrus
(heat).
16:22 Oct 19, 2021
Jkt 256001
PO 00000
section must conform to § 510.455 of
this chapter.
*
*
*
*
*
(e) * * *
(4) * * *
Indications for use
(i) to provide 70 mg/
head/day.
VerDate Sep<11>2014
Frm 00015
Fmt 4700
Sponsor
Sfmt 4700
Feed to provide chlortetracycline at
the rate of 70 mg per animal daily.
A withdrawal period has not been
established in pre-ruminating
calves. Do not use in calves to be
processed for veal.
Melengestrol acetate Type C topdress medicated feed must be top
dressed onto or mixed at feeding
with the Type C medicated feed
containing 5.83 to 14 g/ton chlortetracycline. Chlortetracycline and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
054771
066104
069254
054771
58000
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Combination in grams/
ton
Indications for use
Limitations
(iii) to provide 0.5 mg/lb
of body weight daily.
........................................
Beef cattle (over 700 lb): For control
of active infection of anaplasmosis
caused by Anaplasma marginale
susceptible to chlortetracycline.
(iv) 33.33 to 50 g/ton to
provide 0.5 mg/lb of
body weight per day.
Melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg
melengestrol acetate
per head per day.
Replacement beef heifers over 700
lb: For control of active infection of
anaplasmosis caused by
Anaplasma marginale susceptible
to chlortetracycline and for suppression of estrus (heat).
(v) 25 to 1,100 g/ton to
provide 0.5 mg/lb of
body weight daily.
Lasalocid, 30 to 600 ......
Pasture cattle (slaughter, stocker,
feeder cattle, beef replacement
heifers) over 700 pounds: For control of active infection of
anaplasmosis caused by
Anaplasma marginale susceptible
to chlortetracycline; and for increased rate of weight gain.
(vi) 25 to 1,100 g/ton to
provide 0.5 mg/lb of
body weight daily.
Lasalocid, 30 to 600;
melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg/head/day
melengestrol acetate.
Replacement beef heifers on pasture
over 700 pounds: For control of active infection of anaplasmosis
caused by Anaplasma marginale
susceptible to chlortetracycline, increased rate of weight gain, and
suppression of estrus (heat).
(vii) to provide 0.5 to 2.0
mg/lb of body weight
daily.
........................................
Beef cattle and nonlactating dairy
cattle: As an aid in the control of
active infection of anaplasmosis
caused by Anaplasma marginale
susceptible to chlortetracycline.
Feed to provide chlortetracycline at
the rate of 0.5 mg per pound of
body weight daily in beef cattle
under 700 pounds. Withdraw 48
hours prior to slaughter. To sponsor Nos. 054771 and 069254: Zero
withdrawal time.
Melengestrol acetate Type C topdress medicated feed must be top
dressed onto or mixed at feeding
with a Type C medicated feed containing 33.33 to 50 g/ton chlortetracycline. Feeding a Type C topdress medicated feed containing
melengestrol acetate shall not exceed 24 days. Chlortetracycline
and melengestrol as provided by
No. 054771 in § 510.600(c) of this
chapter.
Feed continuously on a hand-fed
basis 0.5 mg chlortetracycline per
lb. body weight per day and not
less than 60 mg or more than 300
mg lasalocid per head daily in at
least 1 pound of feed. Daily
lasalocid intakes in excess of 200
mg/head/day in pasture cattle have
not been shown to be more effective than 200 mg lasalocid/head/
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is
required. A withdrawal period has
not been established for this product in pre-ruminating calves. Do
not use in calves to be processed
for veal. See § 558.311(d) of this
chapter. Lasalocid as provided by
No. 054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 25 to 1,100 g/ton of
chlortetracycline and 30 to 600 g/
ton lasalocid to provide 0.5 mg
chlortetracycline per lb body weight
per day and not less than 60 mg or
more than 300 mg lasalocid per
head per day in at least 1 pound of
feed. Do not exceed 24 days of
feeding. See § 558.311(d) of this
chapter. Chlortetracycline,
lasalocid, and melengestrol as provided by No. 054771 in
§ 510.600(c) of this chapter.
In free-choice cattle feeds such as
feed blocks or salt-mineral mixes
manufactured from approved Type
A articles. See paragraph (d)(4) of
this section.
lotter on DSK11XQN23PROD with RULES1
Chlortetracycline amount
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00016
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
054771
066104
069254
054771
054771
069254
054771
054771
069254
lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
Indications for use
Limitations
(viii) to provide 10 mg/lb
of body weight daily.
........................................
Calves, beef and nonlactating dairy
cattle: For treatment of bacterial
enteritis caused by Escherichia coli
and bacterial pneumonia caused
by Pasteurella multocida organisms susceptible to chlortetracycline.
(ix) to provide 10 mg/lb
of body weight daily.
........................................
(x) to provide 10 mg/lb of
body weight daily.
Laidlomycin, 5 ................
Calves (up to 250 lb): For the treatment of bacterial enteritis caused
by Escherichia coli susceptible to
chlortetracycline.
Cattle fed in confinement for slaughter: For treatment of bacterial enteritis caused by Escherichia coli
and bacterial pneumonia caused
by Pasteurella multocida organisms susceptible to chlortetracycline; and for increased rate of
weight and improved feed efficiency.
(xi) to provide 10 mg/lb
of body weight daily.
Laidlomycin, 5 to 10 ......
Cattle fed in confinement for slaughter: For treatment of bacterial enteritis caused by Escherichia coli
and bacterial pneumonia caused
by Pasteurella multocida organisms susceptible to chlortetracycline; and for improved feed efficiency.
(xii) 500 to 2,000 to provide 10 mg/lb of body
weight daily.
Lasalocid, 10 to 30 ........
Cattle fed in confinement for slaughter: For treatment of bacterial enteritis caused by Escherichia coli
and bacterial pneumonia caused
by Pasteurella multocida organisms susceptible to chlortetracycline; and for improved feed efficiency.
Feed approximately 400 g/ton, varying with body weight and feed consumption to provide 10 mg/lb per
day. Treat for not more than 5
days. To sponsor No. 054771
(NADAs 048–761 and 046–699)
and to sponsor No. 069254
(ANADA 200–510): May be mixed
in the cattle’s daily ration or administered as a top-dress. In feed including milk replacers withdraw 10
days prior to slaughter. To sponsor
Nos. 054771 and 069254: Zero
withdrawal time. See paragraph
(d)(3) of this section.
A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in
calves to be processed for veal.
Feed continuously at a rate of 30 to
75 mg laidlomycin propionate potassium per head per day for not
more than 5 days. A withdrawal
period has not been established for
this product in pre-ruminating
calves. Do not use in calves to be
processed for veal. See
§ 558.305(d) of this chapter.
Laidlomycin as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously at a rate of 30 to
75 mg laidlomycin propionate potassium per head per day for not
more than 5 days. A withdrawal
period has not been established for
this product in pre-ruminating
calves. Do not use in calves to be
processed for veal. See
§ 558.305(d) of this chapter.
Laidlomycin as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously in complete feed
for not more than 5 days to provide
10 mg chlortetracycline per lb.
body weight per day and not less
than 100 mg or more than 360 mg
lasalocid per head per day. Do not
allow horses or other equines access to feeds containing lasalocid.
No withdrawal period is required. A
withdrawal period has not been established for this product in pre-ruminating calves. Do not use in
calves to be processed for veal.
See § 558.311(d) of this chapter.
Lasalocid as provided by No.
054771 in § 510.600(c) of this
chapter.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00017
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
58001
Sponsor
054771
066104
069254
054771
066104
069254
054771
054771
054771
069254
lotter on DSK11XQN23PROD with RULES1
58002
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
Indications for use
Limitations
(xiii) to provide 10 mg/lb
of body weight daily.
Lasalocid, 25 to 30 ........
Cattle fed in confinement for slaughter: For treatment of bacterial enteritis caused by Escherichia coli
and bacterial pneumonia caused
by Pasteurella multocida organisms susceptible to chlortetracycline; and for increased rate of
weight gain and improved feed efficiency.
(xiv) 500 to 4,000 to provide 10 mg/lb of body
weight daily.
Lasalocid, 30 to 600 ......
Pasture cattle (slaughter, stocker,
feeder cattle, dairy and beef replacement heifers): For treatment
of bacterial enteritis caused by
Escherichia coli and bacterial
pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline; and for increased
rate of weight gain.
(xv) 500 to 4,000 g/ton
to provide 10 mg/lb of
body weight daily.
Lasalocid, 30 to 600:
Melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg/head/day
melengestrol acetate.
Replacement dairy heifers on pasture
less than 20 months of age and replacement beef heifers on pasture:
For treatment of bacterial enteritis
caused by Escherichia coli and
bacterial pneumonia caused by
Pasteurella multocida organisms
susceptible to chlortetracycline, increased rate of weight gain, and
suppression of estrus (heat).
Feed continuously in complete feed
for not more than 5 days to provide
10 mg chlortetracycline per lb.
body weight per day and not less
than 250 mg or more than 360 mg
lasalocid per head per day. Do not
allow horses or other equines access to feeds containing lasalocid.
No withdrawal period is required. A
withdrawal period has not been established for this product in pre-ruminating calves. Do not use in
calves to be processed for veal.
See § 558.311(d) of this chapter.
Lasalocid as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously on a hand-fed
basis for not more than 5 days to
provide 10 mg chlortetracycline per
lb. body weight per day and not
less than 60 mg or more than 300
mg lasalocid per head per day in at
least 1 pound of feed. Daily
lasalocid intakes in excess of 200
mg/head/day in pasture cattle have
not been shown to be more effective than 200 mg lasalocid/head/
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is
required. A withdrawal period has
not been established for this product in pre-ruminating calves. Do
not use in calves to be processed
for veal. See § 558.311(d) of this
chapter. Lasalocid as provided by
No. 054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 500 to 4,000 g/ton of
chlortetracycline and 30 to 600 g/
ton lasalocid to provide 10 mg
chlortetracycline per lb body weight
per day and not less than 60 mg or
more than 300 mg lasalocid per
head per day in at least 1 pound of
feed for not more than 5 days.
After completing feeding of this
combination, continue feeding a
Type C top-dress medicated feed
containing melengestrol acetate
alone for a total time not exceeding
24 days of feeding. See
§ 558.311(d) of this chapter. Chlortetracycline, lasalocid, and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00018
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
054771
069254
054771
069254
054771
lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
Indications for use
Limitations
(xvi) 500 to 4,000 g/ton ..
........................................
Calves, beef and nonlactating dairy
cattle: For the treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella
multocida susceptible to chlortetracycline.
(xvii) 500 to 4,000 g/ton
Decoquinate, 12.9 to
90.8.
Calves, beef and non-lactating dairy
cattle: For the treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline; and for the prevention of coccidiosis caused by
Eimeria bovis and E. zuernii.
(xviii) 500 to 4,000 to
provide 10 mg per
pound of body weight.
Melengestrol acetate,
0.25 to 2 g/ton to provide 0.25 to 0.5 mg
melengestrol acetate
per head per day.
Growing beef heifers fed in confinement for slaughter: For the treatment of bacterial enteritis caused
by Escherichia coli and bacterial
pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline, increased rate of
weight gain, improved feed efficiency, and suppression of estrus
(heat).
(xix) 500 to 4,000 to provide 10 mg per pound
of body weight.
Melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg
melengestrol acetate
per head per day.
Replacement dairy heifers less than
20 months of age and replacement
beef heifers: For the treatment of
bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline, and for suppression of estrus (heat).
Hand feed continuously for not more
than 5 days to provide 10 mg/lb
body weight per day. A withdrawal
period has not been established for
this product in pre-ruminating
calves. Do not use in calves to be
processed for veal. To sponsor No.
054771 under NADA 046–699: 24hour withdrawal period. To sponsor
No. 054771 under NADA 048–761
and No. 069254 under ANADA
200–510: Zero withdrawal period.
Feed at a rate of 1g chlortetracycline
per 100 lb body weight/day and
22.7 mg decoquinate per 100 lb of
body weight/day for not more than
5 days. When it is fully consumed,
resume feeding 22.7 mg
decoquinate per 100 lb of body
weight/day for a total of 28 days to
prevent coccidiosis. A withdrawal
period has not been established for
this product in pre-ruminating
calves. Do not use in calves to be
processed for veal. Do not feed to
animals producing milk for food.
Decoquinate as provided by No.
054771 in § 510.600(c) of this
chapter.
Melengestrol acetate Type C topdress medicated feed must be top
dressed onto or mixed at feeding
with a Type C medicated feed containing 500 to 4,000 g/ton chlortetracycline for not more than 5
days. After completing feeding of
this combination, continue feeding
a Type C top-dress medicated feed
containing melengestrol acetate
alone. Chlortetracycline and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
Melengestrol acetate Type C topdress medicated feed must be top
dressed onto or mixed at feeding
with a Type C medicated feed containing 500 to 4,000 g/ton chlortetracycline for not more than 5
days. After completing feeding of
this combination, continue feeding
a Type C top-dress medicated feed
containing melengestrol acetate
alone for a total time not exceeding
24 days. Use in dairy heifers less
than 20 months of age may cause
drug residues in milk and/or in
calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. Chlortetracycline and melengestrol as
provided by No. 054771 in
§ 510.600(c) of this chapter.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00019
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
58003
Sponsor
054771
069254
054771
069254
054771
054771
58004
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Combination in grams/
ton
Indications for use
Limitations
(xx) 4,000 to 20,000 g/
ton.
........................................
Calves, beef and nonlactating dairy
cattle: For the treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline.
(xxi) 4,000 to 20,000 g/
ton.
Decoquinate, 90.8 to
535.7.
Calves, beef and non-lactating dairy
cattle: For the treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline; and for the prevention of coccidiosis caused by
Eimeria bovis and E. zuernii.
(xxii) 4,000 to 20,000 g/
ton to provide 10 mg/
lb of body weight per
day.
Melengestrol acetate,
0.25 to 2 g/ton to provide 0.25 to 0.5 mg
melengestrol acetate
per head per day.
Growing beef heifers fed in confinement for slaughter: For the treatment of bacterial enteritis caused
by Escherichia coli and bacterial
pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline, and for increased
rate of weight gain, improved feed
efficiency, and suppression of
estrus (heat).
(xxiii) 4,000 to 20,000 g/
ton to provide 10 mg/
lb of body weight per
day.
Melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg
melengestrol acetate
per head per day.
Replacement dairy heifers less than
20 months of age and replacement
beef heifers: For the treatment of
bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline, and for suppression of estrus (heat).
Administer as a top dress, varying
with body weight and feed consumption, to provide 10 mg/lb per
day. Treat for not more than 5
days. A withdrawal period has not
been established for this product in
pre-ruminating calves. Do not use
in calves to be processed for veal.
Feed at a rate of 1g chlortetracycline
per 100 lb body weight/day and
22.7 mg decoquinate per 100 lb of
body weight/day for not more than
5 days. When it is fully consumed,
resume feeding 22.7 mg
decoquinate per 100 lb of body
weight/day for a total of 28 days to
prevent coccidiosis. A withdrawal
period has not been established for
this product in pre-ruminating
calves. Do not use in calves to be
processed for veal. Do not feed to
animals producing milk for food.
Decoquinate as provided by No.
054771 in § 510.600(c) of this
chapter.
Top dress 0.5 to 2 pounds of this
medicated feed containing both
drugs onto or mix at feeding with a
non-medicated feed for not more
than 5 days. After completing feeding of this combination, continue
feeding a Type C top-dress medicated feed containing melengestrol
acetate alone. A withdrawal period
has not been established for this
product in pre-ruminating calves.
Do not use in calves to be processed for veal. Chlortetracycline
and melengestrol as provided by
No. 054771 in § 510.600(c) of this
chapter.
Top dress 0.5 to 2 pounds of this
medicated feed containing both
drugs onto or mix at feeding with a
non-medicated feed for not more
than 5 days. After completing feeding of this combination, continue
feeding a Type C top-dress medicated feed containing melengestrol
acetate alone for a total time not
exceeding 24 days. Use in dairy
heifers less than 20 months of age
may cause drug residues in milk
and/or in calves born to these
cows. A withdrawal period has not
been established for this product in
pre-ruminating calves. Do not use
in calves to be processed for veal.
Chlortetracycline and melengestrol
as provided by No. 054771 in
§ 510.600(c) of this chapter.
lotter on DSK11XQN23PROD with RULES1
Chlortetracycline amount
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00020
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
054771
069254
054771
069254
054771
054771
lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
(xxiv) to provide 350 mg/
head/day.
........................................
Beef cattle: For control of bacterial
pneumonia associated with shipping fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline.
(xxv) to provide 350 mg/
head/day.
........................................
Beef cattle (under 700 lb): For control
of active infection of anaplasmosis
caused by Anaplasma marginale
susceptible to chlortetracycline.
(xxvi) 50 to 350 g/ton to
provide 350 mg/head/
day.
Melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg
melengestrol acetate
per head per day.
Replacement beef heifers under 700
lb: For control of active infection of
anaplasmosis caused by
Anaplasma marginale susceptible
to chlortetracycline and for suppression of estrus (heat).
(xxvii) 20 to 350 g/ton ....
........................................
Beef cattle and replacement dairy
heifers: For control of bacterial
pneumonia associated with shipping fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline.
(xxviii) 20 to 350 g/ton to
provide 350 mg/head/
day.
Melengestrol acetate,
0.25 to 2 g/ton to provide 0.25 to 0.5 mg
melengestrol acetate
per head per day.
Growing beef heifers fed in confinement for slaughter: For control of
bacterial pneumonia associated
with shipping fever complex
caused by Pasteurella spp. susceptible to chlortetracycline, increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Indications for use
Frm 00021
Fmt 4700
Sfmt 4700
Limitations
Feed to provide chlortetracycline at
the rate of 350 mg per animal
daily. A withdrawal period has not
been established for this product in
pre-ruminating calves. Do not use
in calves to be processed for veal.
Withdrawal periods: To sponsor
No. 054771 under NADAs 046–
699 and 049–287, No. 066104
under NADA 092–286, and No.
069254 under NADA 048–480:
Withdraw 48 hours prior to slaughter. To sponsor No. 054771 under
NADA 048–761 and No. 069254
under NADA 138–935 and ANADA
200–510: Zero withdrawal period.
Feed to provide chlortetracycline at
the rate of 350 mg per animal
daily. A withdrawal period has not
been established for this product in
pre-ruminating calves. Do not use
in calves to be processed for veal.
Withdrawal periods: To sponsor
No. 054771 under NADAs 046–
699 and 049–287, No. 066104
under NADA 092–286, and No.
069254 under NADA 048–480:
Withdraw 48 hours prior to slaughter. To sponsor No. 054771 under
NADA 048–761 and No. 069254
under NADA 138–935 and ANADA
200–510: Zero withdrawal period.
Melengestrol acetate Type C topdress medicated feed must be top
dressed or mixed at feeding with
the Type C medicated feed containing 50 to 350 g/ton chlortetracycline for up to 24 days of feeding. Do not exceed 24 days of
feeding. Chlortetracycline and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed to provide chlortetracycline at
the rate of 350 mg per head per
day. This drug is not approved for
use in female dairy cattle 20
months of age or older, including
dry dairy cows. Use in these cattle
may cause drug residues in milk
and/or in calves born to these
cows. A withdrawal period has not
been established for this product in
pre-ruminating calves. Do not use
in calves to be processed for veal.
To sponsor No. 054771 under
NADA 048–761 and No. 069254
under ANADA 200–510: Zero withdrawal period.
Melengestrol acetate Type C topdress medicated feed must be top
dressed onto or mixed at feeding
with the Type C medicated feed
containing 20 to 350 g/ton chlortetracycline. Chlortetracycline and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
E:\FR\FM\20OCR1.SGM
20OCR1
58005
Sponsor
054771
066104
069254
054771
066104
069254
054771
054771
069254
054771
58006
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
lotter on DSK11XQN23PROD with RULES1
Chlortetracycline amount
Combination in grams/
ton
Indications for use
Limitations
Melengestrol acetate Type C topdress medicated feed must be top
dressed or mixed at feeding with
the Type C medicated feed containing 20 to 350 g/ton chlortetracycline. Use in dairy heifers less
than 20 months of age may cause
drug residues in milk and/or in
calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. Chlortetracycline and melengestrol as
provided by No. 054771 in
§ 510.600(c) of this chapter.
Feed continuously at a rate of 30 to
75 mg laidlomycin propionate potassium per head per day. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. See
§ 558.305(d) of this chapter.
Laidlomycin as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously at a rate of 30 to
75 mg laidlomycin propionate potassium per head per day. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. See
§ 558.305(d) of this chapter.
Laidlomycin as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously in complete feed
at a rate of 350 mg chlortetracycline and not less than 250 mg
nor more than 360 mg lasalocid
per head daily. Do not allow
horses or other equines access to
feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. See
§ 558.311(d) of this chapter.
Lasalocid as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously in complete feed
at a rate of 350 mg chlortetracycline and not less than 250 mg
nor more than 360 mg lasalocid
per head daily. Do not allow
horses or other equines access to
feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. See
§ 558.311(d) of this chapter.
Lasalocid as provided by No.
054771 in § 510.600(c) of this
chapter.
(xxix) 20 to 350 g/ton to
provide 350 mg/head/
day.
Melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg
melengestrol acetate
per head per day.
Replacement dairy heifers less than
20 months of age and replacement
beef heifers: For control of bacterial pneumonia associated with
shipping fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline and suppression
of estrus (heat).
(xxx) to provide 350 mg/
head/day.
Laidlomycin, 5 ................
Cattle fed in confinement for slaughter: For control of bacterial pneumonia associated with shipping
fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline; and for increased
rate of weight and improved feed
efficiency.
(xxxi) to provide 350 mg/
head/day.
Laidlomycin, 5 to 10 ......
Cattle fed in confinement for slaughter: For control of bacterial pneumonia associated with shipping
fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline; and for improved
feed efficiency.
(xxxii) 25 to 42.2 g/ton to
provide 350 mg/head/
day.
Lasalocid, 25 to 30 ........
Cattle under 700 pounds fed in confinement for slaughter: For control
of active infection of anaplasmosis
caused by Anaplasma marginale
susceptible to chlortetracycline;
and for increased rate of weight
gain and improved feed efficiency.
(xxxiii) 25 to 42.2 g/ton
to provide 350 mg/
head/day.
Lasalocid, 25 to 30 ........
Cattle fed in confinement for slaughter: For control of bacterial pneumonia associated with shipping
fever complex caused by
Pasteurella multocida organisms
susceptible to chlortetracycline;
and for increased rate of weight
gain and improved feed efficiency.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00022
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
054771
054771
054771
054771
069254
054771
069254
lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
Indications for use
Limitations
(xxxiv) 25 to 100 g/ton to
provide 350 mg/head/
day.
Lasalocid, 10 to 30 ........
Cattle under 700 pounds fed in confinement for slaughter: For control
of active infection of anaplasmosis
caused by Anaplasma marginale
susceptible to chlortetracycline;
and for improved feed efficiency.
(xxxv) 25 to 100 g/ton to
provide 350 mg/head/
day.
Lasalocid, 10 to 30 ........
Cattle fed in confinement for slaughter: For control of bacterial pneumonia associated with shipping
fever complex caused by
Pasteurella multocida organisms
susceptible to chlortetracycline;
and for improved feed efficiency.
(xxxvi) 25 to 700 to provide 350 g/head/day.
Lasalocid, 30 to 600 ......
Pasture cattle (slaughter, stocker,
feeder cattle, dairy and beef replacement heifers): For control of
bacterial pneumonia associated
with shipping fever complex
caused by Pasteurella multocida
organisms susceptible to chlortetracycline; and for increased rate
of weight gain.
(xxxvii) 25 to 700 g/ton
to provide 350 mg/
head/day.
Lasalocid, 30 to 600;
melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg/head/day
melengestrol acetate.
Replacement beef heifers on pasture:
For control of bacterial pneumonia
associated with shipping fever
complex caused by Pasteurella
spp. susceptible to chlortetracycline, increased rate of weight
gain, and suppression of estrus
(heat).
Feed continuously in complete feed
at a rate of 350 mg chlortetracycline and not less than 100 mg
nor more than 360 mg lasalocid
per head daily. Do not allow
horses or other equines access to
feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. See
§ 558.311(d) of this chapter.
Lasalocid as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously in complete feed
at a rate of 350 mg chlortetracycline and not less than 100 mg
nor more than 360 mg lasalocid
per head daily. Do not allow
horses or other equines access to
feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves
to be processed for veal. See
§ 558.311(d) of this chapter.
Lasalocid as provided by No.
054771 in § 510.600(c) of this
chapter.
Feed continuously on a hand-fed
basis at a rate of 350 mg chlortetracycline and not less than 60
mg nor more than 300 mg
lasalocid per head per day in at
least 1 pound of feed. Daily
lasalocid intakes in excess of 200
mg/head/day in pasture cattle have
not been shown to be more effective than 200 mg lasalocid/head/
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is
required. A withdrawal period has
not been established for this product in pre-ruminating calves. Do
not use in calves to be processed
for veal. See § 558.311(d) of this
chapter. Lasalocid as provided by
No. 054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 25 to 700 g/ton of chlortetracycline and 30 to 600 g/ton
lasalocid to provide 350 mg chlortetracycline per head daily and not
less than 60 mg or more than 300
mg lasalocid per head daily in at
least 1 pound of feed. Do not exceed 24 days of feeding. See
§ 558.311(d) of this chapter. Chlortetracycline, lasalocid, and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00023
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
58007
Sponsor
054771
069254
054771
069254
054771
069254
054771
lotter on DSK11XQN23PROD with RULES1
58008
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
(xxxviii) 25 to 700 to provide 350 mg/head/day.
Lasalocid, 30 to 600 ......
Pasture cattle (slaughter, stocker,
feeder cattle, beef replacement
heifers) under 700 pounds: For
control of active infection of
anaplasmosis caused by
Anaplasma marginale susceptible
to chlortetracycline; and for increased rate of weight gain.
(xxxix) 25 to 700 g/ton to
provide 350 mg/head/
day.
Lasalocid, 30 to 600;
melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg/head/day
melengestrol acetate.
Replacement beef heifers on pasture
under 700 pounds: For control of
active infection of anaplasmosis
caused by Anaplasma marginale
susceptible to chlortetracycline, increased rate of weight gain, and
suppression of estrus (heat).
(xl) 25 to 2,800 to provide 350 mg/head/day.
Lasalocid, 30 to 181.8 ...
Beef cattle weighing under 700
pounds: For control of active infection of anaplasmosis caused by
Anaplasma marginale susceptible
to chlortetracycline; and for the
control of coccidiosis caused by
Eimeria bovis and E. zuernii.
(xli) 25 to 2,80 g/ton to
provide 350 mg/head/
day.
Lasalocid, 30 to 181.8;
melengestrol acetate,
0.25 to 2 g/ton to provide 0.25 to 0.5 mg/
head/day melengestrol
acetate.
Growing beef heifers fed in confinement for slaughter under 700
pounds: For control of active infection of anaplasmosis caused by
Anaplasma marginale susceptible
to chlortetracycline, control of coccidiosis caused by Eimeria bovis
and E. zuernii, increased rate of
weight gain, improved feed efficiency, and suppression of estrus
(heat).
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Indications for use
Frm 00024
Fmt 4700
Sfmt 4700
Limitations
Feed continuously on a hand-fed
basis at a rate of 350 mg chlortetracycline and not less than 60
mg nor more than 300 mg
lasalocid per head per day in at
least 1 pound of feed. Daily
lasalocid intakes in excess of 200
mg/head/day in pasture cattle have
not been shown to be more effective than 200 mg lasalocid/head/
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is
required. A withdrawal period has
not been established for this product in pre-ruminating calves. Do
not use in calves to be processed
for veal. See § 558.311(d) of this
chapter. Lasalocid as provided by
No. 054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 25 to 700 g/ton of chlortetracycline and 30 to 600 g/ton
lasalocid to provide 350 mg chlortetracycline per head daily and not
less than 60 mg or more than 300
mg lasalocid per head daily in at
least 1 pound of feed. Do not exceed 24 days of feeding. See
§ 558.311(d) of this chapter. Chlortetracycline, lasalocid, and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
Hand feed continuously at a rate of
350 mg chlortetracycline and 1 mg
lasalocid per 2.2 lb. body weight
daily to cattle with a maximum of
360 mg of lasalocid per head per
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is
required. A withdrawal period has
not been established for this product in pre-ruminating calves. Do
not use in calves to be processed
for veal. See § 558.311(d) of this
chapter. Chlortetracycline and
lasalocid as provided by No.
054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 25 to 2,800 g/ton of
chlortetracycline and 30 to 181.8 g/
ton lasalocid to provide 350 mg
chlortetracycline per head per day
and 1 mg lasalocid per 2.2 lb. of
body weight daily with a maximum
of 360 mg lasalocid per head per
day. See § 558.311(d) of this chapter. Chlortetracycline, lasalocid,
and melengestrol as provided by
No. 054771 in § 510.600(c) of this
chapter.
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
054771
069254
054771
054771
069254
054771
lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
(xlii) 25 to 2,800 to provide 350 mg/head/day.
Lasalocid, 30 to 181.8 ...
Beef cattle weighing up to 800
pounds: For control of bacterial
pneumonia associated with shipping fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline; and for the control of coccidiosis caused by
Eimeria bovis and E. zuernii.
(xliii) 25 to 2,800 g/ton to
provide 350 mg/head/
day.
Lasalocid, 30 to 181.8;
melengestrol acetate,
0.25 to 2 g/ton to provide 0.25 to 0.5 mg/
head/day melengestrol
acetate.
Growing beef heifers fed in confinement for slaughter up to 800
pounds: For control of bacterial
pneumonia associated with shipping fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline, control of coccidiosis caused by Eimeria bovis and
E. zuernii, increased rate of weight
gain, improved feed efficiency, and
suppression of estrus (heat).
(xliv) 25 to 2,800 g/ton to
provide 350 mg/head/
day.
Lasalocid, 30 to 181.8;
melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg/head/day
melengestrol acetate.
Replacement beef heifers up to 800
pounds: For control of bacterial
pneumonia associated with shipping fever complex caused by
Pasteurella spp. susceptible to
chlortetracycline, control of coccidiosis caused by Eimeria bovis and
E. zuernii, and suppression of
estrus (heat).
(xlv) 500 to 4,000 to provide 10 mg/head/day.
Lasalocid, 30 to 181.8 ...
Cattle weighing up to 800 pounds:
For the treatment of bacterial enteritis caused by Escherichia coli
and bacterial pneumonia caused
by Pasteurella multocida susceptible to chlortetracycline; and for
the control of coccidiosis caused
by Eimeria bovis and E. zuernii.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Indications for use
Frm 00025
Fmt 4700
Sfmt 4700
Limitations
Hand feed continuously at a rate of
350 mg chlortetracycline and 1 mg
lasalocid per 2.2 lb. body weight
daily to cattle with a maximum of
360 mg of lasalocid per head per
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is
required. A withdrawal period has
not been established for this product in pre-ruminating calves. Do
not use in calves to be processed
for veal. See § 558.311(d) of this
chapter. Lasalocid as provided by
No. 054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 25 to 2,800 g/ton of
chlortetracycline and 30 to 181.8 g/
ton lasalocid to provide 350 mg
chlortetracycline per head daily
and 1 mg lasalocid per 2.2 lb. of
body weight daily with a maximum
of 360 mg lasalocid per head per
day. See § 558.311(d) of this chapter. Chlortetracycline, lasalocid,
and melengestrol as provided by
No. 054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 25 to 2,800 g/ton of
chlortetracycline and 30 to 181.8 g/
ton lasalocid to provide 350 mg
chlortetracycline per head daily
and 1 mg lasalocid per 2.2 lb. of
body weight daily with a maximum
of 360 mg lasalocid per head per
day. Do not exceed 24 days of
feeding. See § 558.311(d) of this
chapter. Chlortetracycline,
lasalocid, and melengestrol as provided by No. 054771 in
§ 510.600(c) of this chapter.
Hand feed continuously for not more
than 5 days at a rate of 10 mg
chlortetracycline and 1 mg
lasalocid per 2.2 lb. body weight
daily to cattle with a maximum of
360 mg of lasalocid per head per
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is
required. A withdrawal period has
not been established for this product in pre-ruminating calves. Do
not use in calves to be processed
for veal. See § 558.311(d) of this
chapter. Lasalocid as provided by
No. 054771 in § 510.600(c) of this
chapter.
E:\FR\FM\20OCR1.SGM
20OCR1
58009
Sponsor
054771
069254
054771
054771
054771
069254
58010
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Chlortetracycline amount
Combination in grams/
ton
Indications for use
Limitations
(xlvi) 500 to 4,000 g/ton
to provide 10 mg/lb of
body weight daily.
Lasalocid, 30 to 181.8;
melengestrol acetate,
0.25 to 2 g/ton to provide 0.25 to 0.5 mg/
head/day melengestrol
acetate.
Growing beef heifers fed in confinement for slaughter up to 800
pounds: For the treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline, control of coccidiosis caused by Eimeria bovis and
E. zuernii, increased rate of weight
gain, improved feed efficiency, and
suppression of estrus (heat).
(xlvii) 500 to 4,000 g/ton
to provide 10 mg/lb of
body weight daily.
Lasalocid, 30 to 181.8;
melengestrol acetate,
0.5 to 2 g/ton to provide 0.5 mg/head/day
melengestrol acetate.
Replacement dairy heifers up to 800
pounds and less than 20 months of
age and replacement beef heifers
up to 800 pounds: For the treatment of bacterial enteritis caused
by Escherichia coli and bacterial
pneumonia caused by Pasteurella
multocida organisms susceptible to
chlortetracycline, control of coccidiosis caused by Eimeria bovis and
E. zuernii, and suppression of
estrus (heat).
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 500 to 4,000 g/ton of
chlortetracycline and 30 to 181.8 g/
ton lasalocid to provide 10 mg
chlortetracycline per lb of body
weight per day and 1 mg lasalocid
per 2.2 lb of body weight per day
with a maximum of 360 mg
lasalocid per head per day for not
more than 5 days of feeding. After
completing feeding of this combination, continue feeding a Type
C top-dress medicated feed containing melengestrol acetate alone.
See § 558.311(d) of this chapter.
Chlortetracycline, lasalocid, and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
The melengestrol acetate Type C
top-dress medicated feed must be
top dressed onto or mixed at feeding with a Type C medicated feed
containing 500 to 4,000 g/ton of
chlortetracycline and 30 to 181.8 g/
ton lasalocid to provide 10 mg
chlortetracycline per lb of body
weight per day and 1 mg lasalocid
per 2.2 lb of body weight per day
with a maximum of 360 mg
lasalocid per head per day for not
more than 5 days. After completing
feeding of this combination, continue feeding a Type C top-dress
medicated feed containing
melengestrol acetate alone. See
§ 558.311(d) of this chapter. Chlortetracycline, lasalocid, and
melengestrol as provided by No.
054771 in § 510.600(c) of this
chapter.
*
§ 558.342
■
*
lotter on DSK11XQN23PROD with RULES1
*
*
*
*
31. In § 558.342, revise paragraph
(e)(1)(iv) to read as follows:
Melengestrol.
*
*
(e) * * *
*
Indications for use
*
(iv) 0.25 to 0.5 .....
*
Monensin, 10 to 40
*
*
Heifers fed in confinement for slaughter:
For increased rate of weight gain, improved feed efficiency, and suppression
of estrus (heat); and for the prevention
and control of coccidiosis due to Eimeria
bovis and E. zuernii.
Jkt 256001
PO 00000
Frm 00026
Fmt 4700
054771
(1) * * *
Combination in
mg/head/day
16:22 Oct 19, 2021
054771
*
Melengestrol
acetate in
mg/head/day
VerDate Sep<11>2014
Sponsor
Sfmt 4700
Limitations
Sponsor
*
*
*
Add at the rate of 0.5 to 2.0 lb/head/day a
016592
medicated feed (liquid or dry) containing
045771
0.125 to 1.0 mg melengestrol acetate/lb
058198
to a feed containing 10 to 40 g of
monensin per ton to provide 0.25 to 0.5
mg melengestrol acetate/head/day and
0.14 to 0.42 mg monensin/lb body
weight, depending on severity of coccidiosis challenge, up to 480 mg monensin/
head/day. See § 558.355(d) of this chapter. Monensin as provided by No. 016592
or 058198; melengestrol acetate as provided by No. 016952, 054771, or 058198
in § 510.600(c) of this chapter.
E:\FR\FM\20OCR1.SGM
20OCR1
58011
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Melengestrol
acetate in
mg/head/day
Combination in
mg/head/day
*
*
Indications for use
*
*
*
*
*
32. In § 558.355, revise paragraphs
(b)(2), (f)(2)(ii), (f)(3), and (f)(4)(i) and
(ii), remove paragraph (f)(4)(v),
redesignate paragraph (f)(4)(vi) as
paragraph (f)(4)(v) and revise it, and
revise paragraphs (f)(6)(i) and (f)(7)(viii)
Monensin in
grams/ton
*
(ii) 54 to 90 ..........
*
*
§ 558.355
Monensin.
*
*
*
*
*
(b) * * *
(2) No. 016592 for use of a Type A
medicated article containing 90.7 grams
Combination in grams/ton
*
*
*
Limitations
*
*
Growing turkeys: For the prevention of coccidiosis caused by
Eimeria adenoeides, E.
meleagrimitis, and E.
gallopavonis, and for increased
rate of weight gain and improved
feed efficiency.
*
Sponsor
monensin, USP, per pound as in
paragraphs (f)(3), (f)(4)(v), and (f)(6) of
this section.
*
*
*
*
*
(f) * * *
(2) * * *
Indications for use
*
*
Bacitracin methylenedisalicylate, 4
to 50.
*
*
The revisions read as follows:
*
■
Limitations
Sponsor
*
*
Feed continuously as the sole ra058198
tion. The optimum level depends 069254
upon the severity of coccidiosis
exposure. Do not allow horses,
other equines, mature turkeys, or
guinea fowl access to feed containing monensin. Ingestion of
monensin by horses and guinea
fowl has been fatal. Some strains
of turkey coccidia may be
monensin tolerant or resistant.
Monensin may interfere with development of immunity to turkey
coccidiosis. Bacitracin methylene
disalicylate as provided by No.
054771 or 069254 in
§ 510.600(c) of this chapter.
*
*
*
lotter on DSK11XQN23PROD with RULES1
(3) * * *
Monensin in
grams/ton
Indications for use
Limitations
(i) 5 to 40 .............
Growing beef steers and heifers fed in confinement for
slaughter: For improved feed efficiency.
(ii) 10 to 40 ..........
Growing beef steers and heifers fed in confinement for
slaughter: For prevention and control of coccidiosis
due to Eimeria bovis and E. zuernii.
(iii) 10 to 200 .......
Calves excluding veal calves: For prevention and control of coccidiosis due to Eimeria bovis and E.
zuernii.
(iv) 11 to 22 .........
Dairy cows: For increased milk production efficiency
(production of marketable solids-corrected milk per
unit of feed intake).
Dairy cows: For increased milk production efficiency
(production of marketable solids-corrected milk per
unit of feed intake).
Feed continuously in complete feed at a rate of 50 to
480 milligrams of monensin per head per day. No
additional improvement in feed efficiency has been
shown from feeding monensin at levels greater than
30 grams per ton (360 milligrams per head per day).
See special labeling considerations in paragraph (d)
of this section.
Feed at a rate of 0.14 to 0.42 milligram per pound of
body weight per day, depending upon the severity
of challenge, up to maximum of 480 milligrams per
head per day. See special labeling considerations in
paragraph (d) of this section.
Feed at a rate of 0.14 to 1.0 milligram monensin per
pound of body weight per day, depending upon the
severity of challenge, up to maximum of 200 milligrams per head per day. See special labeling considerations in paragraph (d) of this section.
Feed continuously to dry and lactating dairy cows in a
total mixed ration (‘‘complete feed’’). See special labeling considerations in paragraph (d) of this section.
Feed continuously to dry and lactating dairy cows in a
component feeding system (including top dress).
The Type C medicated feed must be fed in a minimum of 1 lb of feed to provide 185 to 660 mg/head/
day monensin to lactating cows or 115 to 410 mg/
head/day monensin to dry cows. See special labeling considerations in paragraph (d) of this section.
(v) 11 to 400 ........
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00027
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
016592
058198
016592
058198
016592
058198
016592
058198
016592
058198
58012
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Monensin in
grams/ton
Indications for use
Limitations
(vi) 15 to 400 .......
Growing beef steers and heifers on pasture (stocker,
feeder, and slaughter) or in a dry lot and replacement beef and dairy heifers: For increased rate of
weight gain, and for prevention and control of coccidiosis due to Eimeria bovis and E. zuernii.
(vii) 25 to 400 ......
Beef cows: For improved feed efficiency when receiving supplemental feed, and for the prevention and
control of coccidiosis due to Eimeria bovis and E.
zuernii.
Sponsor
For increased rate of weight gain, feed at a rate of 50
to 200 milligrams monensin per head per day in not
less than 1 pound of feed or, after the 5th day, feed
at a rate of 400 milligrams per head per day every
other day in not less than 2 pounds of feed. For
prevention and control of coccidiosis, feed at a rate
of 0.14 to 0.42 milligram per pound of body weight
per day, depending on severity of challenge, up to
200 milligrams per head per day. During first 5 days
of feeding, cattle should receive no more than 100
milligrams per day in not less than 1 pound of feed.
See special labeling considerations in paragraph (d)
of this section.
Feed as supplemental feed, either hand-fed in a minimum of 1 pound of feed or mixed in a total ration.
For improved feed efficiency, feed continuously at a
rate of 50 to 200 milligrams monensin per head per
day. For prevention and control of coccidiosis, feed
at a rate of 0.14 to 0.42 milligram per pound of body
weight per day, depending upon severity of challenge, up to a maximum of 200 milligrams per head
per day. During first 5 days of feeding, cattle should
receive no more than 100 milligrams per head per
day in not less than 1 pound of feed. See special labeling considerations in paragraph (d) of this section.
016592
058198
016592
058198
(4) * * *
Monensin amount
(i) 150 milligrams per
pound of protein-mineral block (0.033%).
(ii) 175 milligrams per
pound of protein-mineral block (0.038%).
*
(v) 1,620 grams per ton
of mineral granules as
specified in paragraph
(f)(4)(v)(A) of this section.
Indications for use
Limitations
Sponsor
Growing beef steers and heifers on pasture (stocker, feeder, and slaughter) and replacement beef
heifers on pasture: For increased rate of weight
gain, and for prevention and control of coccidiosis caused by Eimeria bovis and E. zuernii in
pasture cattle which may require supplemental
feed.
Growing beef steers and heifers on pasture (stocker, feeder, and slaughter): For increased rate of
weight gain.
Provide 50 to 200 milligrams of monensin (0.34 to
1.33 pounds of block) per head per day, at least
1 block per 10 to 12 head of cattle. Roughage
must be available at all times. Do not allow animals access to other protein blocks, salt or mineral, while being fed this product. See paragraph
(d)(10)(i) of this section.
Provide 40 to 200 milligrams of monensin (0.25 to
1.13 pounds or 4 to 18 ounces of block) per
head per day, at least 1 block per 4 head of cattle. Do not allow cattle access to salt or mineral
while being fed this product. Ingestion by cattle
of monensin at levels of 600 milligrams per head
per day and higher has been fatal. See paragraph (d)(10)(i) of this section.
*
*
*
Growing beef steers and heifers on pasture (stocker, feeder, and slaughter) or in a dry lot and replacement beef and dairy heifers: For increased
rate of weight gain, and for prevention and control of coccidiosis due to Eimeria bovis and E.
zuernii.
*
*
*
Feed at a rate of 50 to 200 milligrams per head per 016592
day. During the first 5 days of feeding, cattle
058198
should receive no more than 100 milligrams per
day. Do not feed additional salt or minerals. Do
not mix with grain or other feeds. Monensin is
toxic to cattle when consumed at higher than approved levels. Stressed and/or feed- and/or
water-deprived cattle should be adapted to the
pasture and to unmedicated mineral supplement
before using the monensin mineral supplement.
012286
017800
lotter on DSK11XQN23PROD with RULES1
(A) Specifications. Use as free-choice
Type C medicated feed formulated as
mineral granules as follows:
Ingredient
Percent
Monocalcium phosphate (21% phosphorus, 15% calcium) ............................................................................................
Sodium chloride (salt) ......................................................................................................................................................
Dried cane molasses .......................................................................................................................................................
Ground limestone (33% calcium) or calcium carbonate (38% calcium) .........................................................................
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00028
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
29.49
24.37
20.0
13.75
International
feed No.
6–01–082
6–04–152
4–04–695
6–02–632
58013
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Ingredient
Percent
Cane molasses ................................................................................................................................................................
Processed grain by-products (as approved by AAFCO) .................................................................................................
Vitamin/trace mineral premix 1 .........................................................................................................................................
Monensin Type A article, 90.7 grams per pound ............................................................................................................
Antidusting oil ..................................................................................................................................................................
3.0
5.0
2.5
0.89
1.0
International
feed No.
4–04–696
........................
........................
........................
........................
1 Content of vitamin and trace mineral premixes may be varied. However, they should be comparable to those used for other free-choice feeds.
Formulation modifications require FDA approval prior to marketing. Selenium must comply with 21 CFR 573.920. Ethylenediamine dihydroiodide
should comply with FDA Compliance Policy Guide Sec. 651.100 (CPG 7125.18).
*
(B) [Reserved]
*
*
*
(6) * * *
*
Monensin in
grams/ton
Indications for use
(i) 20 ....................
*
Goats maintained in confinement: For the prevention
of coccidiosis caused by Eimeria crandallis, E.
christenseni, and E. ninakohlyakimovae.
*
*
(7) * * *
(viii) Ractopamine as in § 558.500.
*
*
*
*
*
Ractopamine
in grams/ton
lotter on DSK11XQN23PROD with RULES1
Limitations
Feed continuously. Do not feed to lactating goats. See
paragraph (d)(11) of this section for provisions for
monensin liquid Type C goat feeds.
*
*
33. In § 558.500, revise paragraphs
(e)(2)(ii), (iv), (v), and (vii) to read as
follows:
■
Combination in
grams/ton
Sponsor
*
§ 558.500
*
*
Ractopamine.
*
*
(e) * * *
(2) * * *
Indications for use
016592
058198
*
*
Limitations
Sponsor
*
*
*
(ii) 8.2 to 24.6 to provide Monensin 10 to 40 to
70 to 430 mg/head/day.
provide 0.14 to 0.42
mg monensin/lb of
body weight, depending on severity of coccidiosis challenge, up
to 480 mg/head/day.
*
*
*
Cattle fed in confinement for slaughFeed continuously as sole ration durter: For increased rate of weight
ing the last 28 to 42 days on feed.
gain, improved feed efficiency, and
Not for animals intended for breedprevention and control of coccidiing. See special labeling considerosis due to Eimeria bovis and E.
ations in § 558.355(d) of this chapzuernii during the last 28 to 42
ter. Ractopamine as provided by
days on feed.
No. 016592, 054771, or 058198;
monensin as provided by No.
016592 or 058198 in § 510.600(c)
of this chapter.
*
016592
054771
058198
*
*
*
(iv) 9.8 to 24.6 to provide Monensin 10 to 40 to
90 to 430 mg/head/day.
provide 0.14 to 0.42
mg monensin/lb of
body weight, depending on severity of coccidiosis challenge, up
to 480 mg/head/day.
*
*
*
Cattle fed in confinement for slaughFeed continuously as sole ration durter: For increased rate of weight
ing the last 28 to 42 days on feed.
gain, improved feed efficiency, inNot for animals intended for breedcreased carcass leanness, and
ing. See special labeling considerprevention and control of coccidiations in § 558.355(d) of this chaposis due to Eimeria bovis and E.
ter. Ractopamine as provided by
zuernii during the last 28 to 42
No. 016592, 054771, or 058198;
days on feed.
monensin as provided by No.
016592 or 058198 in § 510.600(c)
of this chapter.
Heifers fed in confinement for slaugh- Feed continuously as sole ration durter: For increased rate of weight
ing the last 28 to 42 days on feed.
gain, improved feed efficiency, inNot for animals intended for breedcreased carcass leanness, prevening. See special labeling considertion and control of coccidiosis due
ations in §§ 558.342(d) and
to Eimeria bovis and E. zuernii,
558.355(d) of this chapter.
and suppression of estrus (heat)
Ractopamine as provided by No.
during the last 28 to 42 days on
016592, 054771, or 058198;
feed.
monensin as provided by No.
016592 or 058198; melengestrol
acetate as provided by No.
016592, 054771 or 058198 in
§ 510.600(c) of this chapter.
*
016592
054771
058198
(v) 9.8 to 24.6 to provide Monensin 10 to 40 to
90 to 430 mg/head/day.
provide 0.14 to 0.42
mg monensin/lb of
body weight, depending on severity of coccidiosis challenge, up
to 480 mg/head/day,
plus melengestrol acetate to provide 0.25 to
0.5 mg/head/day.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00029
Fmt 4700
Sfmt 4700
E:\FR\FM\20OCR1.SGM
20OCR1
016592
054771
058198
58014
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Ractopamine
in grams/ton
Combination in
grams/ton
*
(vii) Not to exceed 800;
to provide 70 to 400
mg/head/day.
*
*
Monensin 10 to 40 to
provide 0.14 to 0.42
mg monensin/lb of
body weight, depending on severity of coccidiosis challenge, up
to 480 mg/head/day.
*
*
*
Indications for use
*
*
*
*
*
*
Cattle fed in confinement for slaughTop dress ractopamine at a minimum
ter: For increased rate of weight
of 1.0 lb/head/day of medicated
gain, improved feed efficiency, and
feed continuously during the last
prevention and control of coccidi28 to 42 days on feed. Not for aniosis due to Eimeria bovis and E.
mals intended for breeding. See
zuernii during the last 28 to 42
special labeling considerations in
days on feed.
§ 558.355(d) of this chapter.
Ractopamine as provided by No.
016592, 054771, or 058198;
monensin as provided by No.
016592 or 058198 in § 510.600(c)
of this chapter.
*
*
§ 558. 550
*
34. In § 558. 550, revise paragraphs
(a), (b), (e)(1)(i), and (e)(2)(i) to read as
follows:
■
Limitations
*
Salinomycin.
(a) Specifications. Type A medicated
articles containing 30 or 60 grams of
salinomycin sodium activity per pound.
Salinomycin in
grams/ton
Combination in
grams/ton
Indications for use
(i) 40 to 60 ...........
...........................
Broiler, roaster, and replacement (breeder
and layer) chickens: For the prevention of
coccidiosis caused by Eimeria tenella, E.
necatrix, E. acervulina, E. maxima, E.
brunetti, and E. mivati.
*
*
*
*
Sponsor
*
016592
054771
058198
*
(b) Sponsor. See No. 016592 in
§ 510.600(c) of this chapter for use as in
paragraph (e) of this section.
*
*
*
*
*
(e) * * *
(1) * * *
Limitations
*
Feed continuously as sole ration. Do not
feed to birds producing eggs for human
consumption. May be fatal if accidentally
fed to adult turkeys or horses.
*
*
Sponsor
016592
*
(2) * * *
Salinomycin in
grams/ton
Combination in
grams per ton
Indications for use
(i) 50 ....................
...........................
Quail: For the prevention of coccidiosis
caused by Eimeria dispersa and E. lettyae.
*
*
*
lotter on DSK11XQN23PROD with RULES1
*
*
§ 558.625
■
*
*
*
*
*
35. In § 558.625, revise paragraphs
(e)(2)(i) and (e)(2)(ix) through (xiii) to
read as follows:
Limitations
*
*
Indications for use
(i) 8 to 10 .................
.................................
Beef cattle: For reduction of incidence of
liver abscesses caused by
Fusobacterium necrophorum and
Arcanobacterium pyogenes.
Jkt 256001
PO 00000
*
*
Combination in
grams/ton
16:22 Oct 19, 2021
*
016592
Tylosin.
*
*
(e) * * *
(2) * * *
Tylosin grams/ton
VerDate Sep<11>2014
Feed continuously as sole ration. Do not
feed to birds producing eggs for human
consumption. May be fatal if accidentally
fed to adult turkeys or horses.
Sponsor
Frm 00030
Fmt 4700
Sfmt 4700
Limitations
Feed continuously as the sole ration to
provide 60 to 90 mg/head/day tylosin.
E:\FR\FM\20OCR1.SGM
20OCR1
Sponsor
016592
054771
058198
066104
lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Tylosin grams/ton
Combination in
grams/ton
Indications for use
*
(ix) 8 to 10 ...............
*
Monensin 10 to 40
plus melengestrol
0.25 to 2.0.
*
*
Heifers fed in confinement for slaughter:
For reduction of incidence of liver abscesses caused by Fusobacterium
necrophorum and Arcanobacterium
pyogenes; for prevention and control of
coccidiosis caused by Eimeria bovis
and E. zuernii; and for increased rate
of weight gain, improved feed efficiency, and suppression of estrus
(heat).
(x) 8 to 10 ................
Monensin 10 to 40
plus ractopamine
8.2 to 24.6.
Cattle fed in confinement for slaughter:
For reduction of incidence of liver abscesses caused by Fusobacterium
necrophorum and Arcanobacterium
pyogenes; for prevention and control of
coccidiosis caused by Eimeria bovis
and E. zuernii; and for increased rate
of weight gain and improved feed efficiency in cattle fed in confinement for
slaughter for the last 28 to 42 days on
feed.
(xi) 8 to 10 ...............
Monensin 10 to 40
plus ractopamine,
not to exceed 800.
Cattle fed in confinement for slaughter:
For reduction of incidence of liver abscesses caused by Fusobacterium
necrophorum and Arcanobacterium
pyogenes; for prevention and control of
coccidiosis caused by Eimeria bovis
and E. zuernii; and for increased rate
of weight gain and improved feed efficiency in cattle fed in confinement for
slaughter for the last 28 to 42 days on
feed.
VerDate Sep<11>2014
16:22 Oct 19, 2021
Jkt 256001
PO 00000
Frm 00031
Fmt 4700
Sfmt 4700
Limitations
58015
Sponsor
*
*
*
Feed continuously as sole ration to heif016592
ers at a rate of 0.5 to 2 pounds per
054771
head per day to provide 0.25 to 0.5
058198
mg/head/day melengestrol acetate and
0.14 to 0.42 mg monensin/lb body
weight per day, depending on the severity of the coccidiosis challenge, up
to 480 mg/head/day and 60 to 90 mg/
head/day tylosin. The melengestrol acetate portion of this Type C medicated
feed must be mixed into the complete
feed containing 10 to 40 g/ton
monensin and 8 to 10 g/ton tylosin at
feeding into the amount of complete
feed consumed by an animal per day.
A withdrawal time has not been established for pre-ruminating calves. Do not
use in calves to be processed for veal.
See §§ 558.342(d) and 558.355(d) of
this chapter. Tylosin provided by No.
016592 or 058198; monensin as provided by No. 016592 or 058198;
melengestrol provided by No. 016592,
054771, or 058198 in § 510.600(c) of
this chapter.
Feed continuously as sole ration to pro016592
vide 70 to 430 mg/head/day
054771
ractopamine and 0.14 to 0.42 mg
058198
monensin/lb body weight per day, depending on the severity of the coccidiosis challenge, up to 480 mg/head/day
and 60 to 90 mg/head/day tylosin for
the last 28 to 42 days on feed. A withdrawal time has not been established
for pre-ruminating calves. Do not use in
calves to be processed for veal. See
special labeling considerations in
§§ 558.355(d) and 558.500(d) of this
chapter. Tylosin provided by No.
016592 or 058198; monensin as provided by No. 016592 or 058198;
ractopamine provided by No. 016592,
054771, or 058198 in § 510.600(c) of
this chapter.
Feed a minimum of 1.0 lb/head/day
016592
ractopamine Type C top dress feed
054771
continuously to cattle fed in confine058198
ment for slaughter, to provide 70 to
400 mg/head/day ractopamine for the
last 28 to 42 days on feed. Feed on
top of a ration containing 10 to 40 g/ton
monensin and 8 to 10 g/ton tylosin
phosphate, to provide 0.14 to 0.42 mg
monensin/lb body weight/day, depending on the severity of the coccidiosis
challenge, up to 480 mg/head/day and
60 to 90 mg/head/day tylosin. A withdrawal time has not been established
for pre-ruminating calves. Do not use in
calves to be processed for veal. See
special labeling considerations in
§§ 558.355(d) and 558.500(d) of this
chapter. Tylosin provided by No.
016592 or 058198; monensin as provided by No. 016592 or 058198;
ractopamine provided by No. 016592,
054771, or 058198 in § 510.600(c) of
this chapter.
E:\FR\FM\20OCR1.SGM
20OCR1
58016
Federal Register / Vol. 86, No. 200 / Wednesday, October 20, 2021 / Rules and Regulations
Tylosin grams/ton
Combination in
grams/ton
Limitations
Feed continuously as sole ration to provide 90 to 430 mg/head/day
ractopamine and 0.14 to 0.42 mg
monensin/lb body weight per day, depending on the severity of the coccidiosis challenge, up to 480 mg/head/day
and 60 to 90 mg/head/day tylosin for
the last 28 to 42 days on feed. A withdrawal time has not been established
for pre-ruminating calves. Do not use in
calves to be processed for veal. See
special labeling considerations in
§§ 558.355(d) and 558.500(d) of this
chapter. Tylosin as provided by No.
016592 or 058198; monensin as provided by No. 016592 or 058198;
ractopamine as provided by No.
016592, 054771, or 058198 in
§ 510.600(c) of this chapter.
Feed continuously as sole ration to provide 90 to 430 mg/head/day
ractopamine and 0.14 to 0.42 mg
monensin/lb body weight per day, depending on the severity of the coccidiosis challenge, up to 480 mg/head/day
and 60 to 90 mg/head/day tylosin for
the last 28 to 42 days on feed. Feed
melengestrol as a top dress or mixed
with a complete ration at the rate of 0.5
to 2.0 pound/head/day (specify one
level) to provide 0.25 to 0.5 mg
melengestrol acetate/head/day (specify
one level). A withdrawal time has not
been established for pre-ruminating
calves. Do not use in calves to be
processed for veal. See special labeling considerations in §§ 558.342(d),
558.355(d), and 558.500(d) of this
chapter. Tylosin provided by No.
016592 or 058198; monensin as provided by No. 016592 or 058198;
ractopamine as provided by No.
016592, 054771, or 058198;
melengestrol acetate as provided by
No. 016592 or 054771 in § 510.600(c)
of this chapter.
(xii) 8 to 10 ..............
Monensin 10 to 40
plus ractopamine
9.8 to 24.6.
Cattle fed in confinement for slaughter:
For reduction of incidence of liver abscesses caused by Fusobacterium
necrophorum and Arcanobacterium
pyogenes; for prevention and control of
coccidiosis caused by Eimeria bovis
and E. zuernii; and for increased rate
of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for
slaughter for the last 28 to 42 days on
feed.
(xiii) 8 to 10 ..............
Monensin, 10 to 40
plus ractopamine,
9.8 to 24.6, plus
melengestrol,
0.125 to 1 mg/lb.
Heifers fed in confinement for slaughter:
For reduction of incidence of liver abscesses caused by Fusobacterium
necrophorum and Arcanobacterium
pyogenes; for prevention and control of
coccidiosis caused by Eimeria bovis
and E. zuernii; for increased rate of
weight gain, improved feed efficiency,
and increased carcass leanness; and
suppression of estrus (heat) in heifers
fed in confinement for slaughter for the
last 28 to 42 days on feed.
*
*
*
*
*
*
*
*
DEPARTMENT OF THE TREASURY
Office of Foreign Assets Control
31 CFR Part 591
Publication of Venezuela Web General
License 7 and Subsequent Iterations
Office of Foreign Assets
Control, Treasury.
AGENCY:
Jkt 256001
The Department of the
Treasury’s Office of Foreign Assets
Control (OFAC) is publishing four
Venezuela-related web general licenses
(GLs) in the Federal Register: GL 7, GL
7A, and GL 7B, each of which is now
expired and was previously issued on
OFAC’s website, as well as GL 7C,
which was also previously issued on
OFAC’s website.
DATES: GL 7C was issued on August 5,
2019. See SUPPLEMENTARY INFORMATION
of this document for additional relevant
dates.
FOR FURTHER INFORMATION CONTACT:
OFAC: Assistant Director for Licensing,
202–622–2480; Assistant Director for
SUMMARY:
BILLING CODE 4164–01–P
16:22 Oct 19, 2021
*
Publication of web general
licenses.
[FR Doc. 2021–22604 Filed 10–19–21; 8:45 am]
VerDate Sep<11>2014
*
ACTION:
Dated: October 12, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
lotter on DSK11XQN23PROD with RULES1
Indications for use
PO 00000
Frm 00032
Fmt 4700
Sfmt 4700
*
Sponsor
016592
054771
058198
016592
054771
058198
*
Regulatory Affairs, 202–622–4855; or
Assistant Director for Sanctions
Compliance & Evaluation, 202–622–
2490.
SUPPLEMENTARY INFORMATION:
Electronic Availability
This document and additional
information concerning OFAC are
available on OFAC’s website:
www.treasury.gov/ofac.
Background
On March 8, 2015, the President,
invoking the authority of, inter alia, the
International Emergency Economic
Powers Act (50 U.S.C. 1701–1706),
issued Executive Order (E.O.) 13692,
‘‘Blocking Property and Suspending
Entry of Persons Contributing to the
E:\FR\FM\20OCR1.SGM
20OCR1
Agencies
[Federal Register Volume 86, Number 200 (Wednesday, October 20, 2021)]
[Rules and Regulations]
[Pages 57992-58016]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-22604]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 510, 516, 520, 522, 526, 556 and 558
[Docket No. FDA-2021-N-0002]
New Animal Drugs; Approval of New Animal Drug Applications;
Changes of Sponsorship
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; technical amendments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is amending the
animal drug regulations to reflect application-related actions for new
animal drug applications (NADAs), abbreviated new animal drug
applications (ANADAs), and conditional new animal drug applications
(cNADAs) during January, February, and March 2021. FDA is informing the
public of the availability of summaries of the basis of approval and of
environmental review documents, where applicable. The animal drug
regulations are also being amended to improve the accuracy and
readability of the regulations.
DATES: This rule is effective October 20, 2021.
FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for
Veterinary Medicine (HFV-6), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 240-402-5689,
[email protected].
SUPPLEMENTARY INFORMATION:
I. Approvals
FDA is amending the animal drug regulations to reflect approval
actions for NADAs, ANADAs, and conditional approval actions for cNADAs
during January, February, and March 2021, as listed in table 1. In
addition, FDA is informing the public of the availability, where
applicable, of documentation of environmental review required under the
National Environmental Policy Act (NEPA) and, for actions requiring
review of safety or effectiveness data, summaries of the basis of
approval (FOI Summaries) under the Freedom of Information Act (FOIA).
These public documents may be seen in the office of the Dockets
Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday
through Friday, 240-402-7500. Persons with access to the internet may
obtain these documents at the CVM FOIA Electronic Reading Room: https://www.fda.gov/about-fda/center-veterinary-medicine/cvm-foia-electronic-reading-room. Marketing exclusivity and patent information may be
accessed in FDA's publication, Approved Animal Drug Products Online
(Green Book) at: https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book.
FDA has verified the website addresses as of the date this document
publishes in the Federal Register, but websites are subject to change
over time.
Table 1--Original and Supplemental NADAs and ANADAs Approved During January, February, and March 2021
--------------------------------------------------------------------------------------------------------------------------------------------------------
Approval date File No. Sponsor Product name Species Effect of the action Public documents
--------------------------------------------------------------------------------------------------------------------------------------------------------
January 8, 2021.............. 141-336 ECO LLC, 344 Nassau AIVLOSIN (62.5% w/w Swine.............. Supplemental FOI Summary.
St., Princeton, NJ tylvalosin as approval for the
08540. tylvalosin tartrate) addition of
Water Soluble Mycoplasma
Granules. hyopneumoniae to
the list of
pathogens for the
control of swine
respiratory disease
indication.
January 11, 2021............. 141-526 Anivive Lifesciences, LAVERDIA-CA1 Dogs............... Conditional approval FOI Summary.
Inc., 3250 Airflite (verdinexor tablets). for the treatment
Way, Suite 400, Long of lymphoma in dogs.
Beach, CA 90807.
January 12, 2021............. 200-675 Huvepharma EOOD, 5th Ractopamine Cattle............. Original approval as FOI Summary.
Floor, 3A Nikolay hydrochloride and a generic copy of
Haytov Str., 1113 monensin Type B and NADA 141-225.
Sofia, Bulgaria. Type C medicated
feeds.
January 12, 2021............. 200-676 Do................... Ractopamine Cattle............. Original approval as FOI Summary.
hydrochloride, a generic copy of
monensin, and NADA 141-224.
tylosin phosphate
Type B and Type C
medicated feeds.
[[Page 57993]]
January 12, 2021............. 200-677 Do................... Ractopamine Cattle............. Original approval as FOI Summary.
hydrochloride, a generic copy of
monensin, and NADA 141-234.
melengestrol acetate
Type C medicated
feeds.
January 12, 2021............. 200-678 Do................... Ractopamine Cattle............. Original approval as FOI Summary.
hydrochloride, a generic copy of
monensin, tylosin NADA 141-233.
phosphate, and
melengestrol acetate
Type C medicated
feeds.
January 14, 2021............. 141-544 Pegasus Laboratories, KBROVET-CA1 Dogs............... Conditional approval FOI Summary.
Inc., 8809 Ely Rd., (potassium bromide for the control of
Pensacola, FL 32514. chewable tablets) seizures associated
Chewable Tablet. with idiopathic
epilepsy in dogs.
January 15, 2021............. 141-539 Neogen Corp., 944 THYROKARE Dogs............... Original approval FOI Summary.
Nandino Blvd., (levothyroxine for replacement
Lexington, KY 40511. sodium tablets). therapy for
diminished thyroid
function in dogs.
February 1, 2021............. 200-683 Huvepharma EOOD, 5th Melengestrol acetate Cattle............. Original approval as FOI Summary.
Floor, 3A Nikolay and monensin Type C a generic copy of
Haytov Str., 1113 medicated feeds. NADA 125-476.
Sofia, Bulgaria.
February 1, 2021............. 200-684 Do................... Ractopamine Cattle............. Original approval as FOI Summary.
hydrochloride, a generic copy of
monensin, and NADA 141-234.
melengestrol acetate
Type C medicated
feeds.
February 1, 2021............. 200-685 Do................... Melengestrol acetate, Cattle............. Original approval as FOI Summary.
monensin, and a generic copy of
tylosin phosphate NADA 138-870.
Type C medicated
feeds.
February 1, 2021............. 200-686 Do................... Monensin, ractopamine Cattle............. Original approval as FOI Summary.
hydrochloride, a generic copy of
tylosin phosphate, NADA 141-233.
and melengestrol
acetate Type C
medicated feeds.
February 8, 2021............. 200-466 Sparhawk SPARMECTIN Plus Cattle............. Supplemental FOI Summary.
Laboratories, Inc., Clorsulon approval reducing
12340 Santa Fe Trail (ivermectin and preslaughter
Dr., Lenexa, KS clorsulon) Injection. withdrawal period
66215. to 21 days.
February 16, 2021............ 200-506 Chanelle ANIMEC PLUS Cattle............. Original approval as FOI Summary.
Pharmaceuticals (ivermectin and a generic copy of
Manufacturing Ltd., clorsulon) Injection. NADA 140-833.
Loughrea, County
Galway, Ireland.
February 18, 2021............ 200-657 Bimeda Animal Health MACROSYN Cattle............. Original approval as FOI Summary.
Ltd., 1B The Herbert (tulathromycin a generic copy of
Building, The Park, injection) NADA 141-244.
Carrickmines, Dublin Injectable Solution.
18, Ireland.
February 18, 2021............ 200-666 Elanco US Inc., 2500 INCREXXA Cattle............. Original approval as FOI Summary.
Innovation Way, (tulathromycin a generic copy of
Greenfield, IN 46140. injection) NADA 141-244.
Injectable Solution.
February 26, 2021............ 141-540 Pharmgate, Inc., 1800 PENNITRACIN MD Turkeys............ Original approval FOI Summary.
Sir Tyler Dr., (bacitracin Type A for the prevention
Wilmington, NC 28405. medicated article) of coccidiosis
and COBAN (monensin caused by Eimeria
Type A medicated adenoeides, E.
article) to be used meleagrimitis and
in the manufacture E. gallopavonis,
of Type C medicated and for increased
feeds. rate of weight gain
and improved feed
efficiency in
growing turkeys.
March 11, 2021............... 200-699 Akorn Animal Health, Dexmedetomidine Dogs and cats...... Original approval as FOI Summary.
Inc., 1925 West Hydrochloride a generic copy of
Field Ct., Suite Injection NADA 141-267.
300, Lake Forest, IL (dexmedetomidine
60045. hydrochloride).
[[Page 57994]]
March 15, 2021............... 141-530 Zoetis Inc., 333 MGA (melengestrol Cattle............. Original approval FOI Summary.
Portage St., acetate Type A for increased rate
Kalamazoo, MI 49007. medicated article) of weight gain,
and AUREOMYCIN improved feed
(chlortetracycline efficiency, and
Type A medicated suppression of
article) to be used estrus (heat) in
in the manufacture replacement dairy
of Type C medicated and beef heifers,
feeds. or growing beef
heifers fed in
confinement for
slaughter receiving
medicated feed
containing
chlortetracycline
for the treatment
of bacterial
enteritis or
pneumonia, control
of bacterial
pneumonia
associated with
shipping fever
complex, reduction
of incidence of
liver abscesses,
and control of
active infection of
anaplasmosis.
March 19, 2021............... 141-531 Do................... MGA (melengestrol Cattle............. Original approval FOI Summary.
acetate Type A for suppression of
medicated article), estrus (heat) in
AUREOMYCIN replacement dairy
(chlortetracycline and beef heifers,
Type A medicated or growing beef
article), and heifers fed in
BOVATEC (lasalocid confinement for
Type A medicated slaughter receiving
article) to be used medicated feed
in the manufacture containing
of Type C medicated chlortetracycline
feeds. for the treatment
of bacterial
enteritis or
pneumonia, control
of bacterial
pneumonia
associated with
shipping fever
complex, or control
of active infection
of anaplasmosis;
and lasalocid for
control of
coccidiosis,
increased rate of
weight gain, and
improved feed
efficiency.
March 22, 2021............... 200-625 Bimeda Animal Health KETOMED (ketoprofen) Horses............. Original approval as FOI Summary.
Ltd., 1B The Herbert Sterile Solution. a generic copy of
Building, The Park, NADA 140-269.
Carrickmines, Dublin
18, Ireland.
March 24, 2021............... 132-872 Intervet, Inc., 2 SAFE-GUARD Cattle............. Supplemental FOI Summary.
Giralda Farms, (fenbendazole) Paste approval providing
Madison, NJ 07940. 10%. for tolerances, a
tissue withdrawal
period, and a milk
discard time in
accordance with a
repartitioning of
the acceptable
daily intake; and
the addition of
indications for
fourth[dash]stage
larvae of certain
endoparasites.
--------------------------------------------------------------------------------------------------------------------------------------------------------
II. Changes of Sponsor
The sponsors of the following approved applications have informed
FDA that they have transferred ownership of, and all rights and
interest in, these applications to another sponsor:
----------------------------------------------------------------------------------------------------------------
File No. Product name Transferring sponsor New sponsor 21 CFR section
----------------------------------------------------------------------------------------------------------------
141-175.................. CAPSTAR (nitenpyram) Elanco US Inc., 2500 Sergeant's Pet Care 520.1510.
Tablets. Innovation Way, Products, Inc.,
Greenfield, IN 10077 S 134th St.,
46140. Omaha, NE 68138.
141-120.................. CLOMICALM Do.................. Virbac AH, Inc., 520.455.
(clomipramine P.O. Box 162059,
hydrochloride) Fort Worth, TX
Tablets. 76161.
141-474.................. ITRAFUNGOL Do.................. Do.................. 520.1189.
(itraconazole oral
solution).
065-081.................. GO-DRY (penicillin G G. C. Hanford Mfg. HQ Specialty Pharma 526.1696.
procaine) Co., P.O. Box 1017, Corp., 120 Rte. 17
Intramammary Syracuse, NY 13201. North, Suite 130,
Infusion. Paramus, NJ 07652.
200-335.................. Ampicillin Sodium Do.................. Do.................. 522.90c.
Powder for
Injection.
200-372.................. HAN-PEN (penicillin Do.................. Do.................. 520.1696a.
G potassium)
Soluble Powder.
065-071.................. Chlortetracycline Huvepharma EOOD, 5th Pharmgate Inc., 1800 520.441.
(chlortetracycline Floor, 3A Nikolay Sir Tyler Dr.,
hydrochloride) Haytov Str., 1113 Wilmington, NC
Soluble Powder. Sofia, Bulgaria. 28405.
065-440.................. CHLORONEX Do.................. Do.................. Do.
(chlortetracycline
hydrochloride)
Soluble Powder.
200-441.................. A[dash]MYCIN Do.................. Do.................. Do.
(chlortetracycline
hydrochloride)
Soluble Powder.
200-528.................. SAVALAN 60 Pharmgate Inc., 1800 Huvepharma EOOD, 5th 558.550.
(salinomycin Sir Tyler Dr., Floor, 3A Nikolay
sodium) Type A Wilmington, NC Haytov Str., 1113
medicated article. 28405. Sofia, Bulgaria.
[[Page 57995]]
200-237.................. Isoflurane, U.S.P... Piramal Enterprises Piramal Pharma Ltd., N/A.
Ltd., Ananta, Ground Floor,
Agastya Corporate Piramal Ananta,
Park, Opp Fire Agastya Corporate
Brigade, Kamani Park, Mumbai,
Junction, LBS Mag Maharashtra,
Kurla (West), 400070, India.
Mumbai, 400070,
India.
----------------------------------------------------------------------------------------------------------------
Following these changes of sponsorship, G. C. Hanford Manufacturing
Co. and Piramal Enterprises Ltd. are no longer the sponsor of an
approved application. Accordingly, the regulations in 21 CFR 510.600(c)
are being amended to reflect these changes.
III. Technical Amendments
FDA is making the following amendments to improve the accuracy,
consistency, and readability of the animal drug regulations:
21 CFR 510.600 is amended by revising the entries for
Cronus Pharma Specialities India Private Ltd. to reflect the correct
address for the firm.
21 CFR 520.2090 is amended to reflect the current approved
indications for use for sarolaner, moxidectin, and pyrantel tablets.
21 CFR 522.970 is amended to reflect the approved species
for a flunixin injectable solution.
21 CFR 558.76 for use of bacitracin methylenedisalicylate
in medicated feed is amended to reflect a current tabular format
organized by species.
21 CFR 558.128 is amended to reflect sponsors of
combination medicated feeds containing chlortetracycline for which
there is no preslaughter withdrawal period.
21 CFR 558.355 for use of monensin in medicated feeds is
amended to reflect the sponsor of an approved generic product and to
remove a redundant condition of use.
IV. Legal Authority
This final rule is issued under section 512(i) of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(i)), which requires
Federal Register publication of ``notice[s] . . . effective as a
regulation,'' of the conditions of use of approved new animal drugs.
This rule sets forth technical amendments to the regulations to codify
recent actions on approved new animal drug applications and corrections
to improve the accuracy of the regulations, and as such does not impose
any burden on regulated entities.
Although denominated a rule pursuant to the FD&C Act, this document
does not meet the definition of ``rule'' in 5 U.S.C. 804(3)(A) because
it is a ``rule of particular applicability.'' Therefore, it is not
subject to the congressional review requirements in 5 U.S.C. 801-808.
Likewise, this is not a rule subject to Executive Order 12866, which
defines a rule as ``an agency statement of general applicability and
future effect, which the agency intends to have the force and effect of
law, that is designed to implement, interpret, or prescribe law or
policy or to describe the procedure or practice requirements of an
agency.''
List of Subjects
21 CFR Part 510
Administrative practice and procedure, Animal drugs, Labeling,
Reporting and recordkeeping requirements.
21 CFR Part 516
Administrative practice and procedure, Animal drugs, Confidential
business information, Reporting and recordkeeping requirements.
21 CFR Parts 520, 522, and 526
Animal drugs.
21 CFR Part 556
Animal drugs, Food.
21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food, Drug, and Cosmetic Act, 21 CFR
parts 510, 516, 520, 522, 526, 556, and 558 are amended as follows:
PART 510--NEW ANIMAL DRUGS
0
1. The authority citation for part 510 continues to read as follows:
Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.
0
2. In Sec. 510.600:
0
a. In the table in paragraph (c)(1):
0
i. Add in alphabetical order an entry for ``Anivive Lifesciences,
Inc.'';
0
ii. Revise the entry for ``Cronus Pharma Specialities India Private
Ltd.'';
0
iii. Remove the entries for ``G. C. Hanford Manufacturing Co.'' and
``Piramal Enterprises Ltd.''; and
0
iv. Add in alphabetical order an entry for ``Piramal Pharma Ltd.''; and
0
b. In the table in paragraph (c)(2):
0
i. Remove the entry for ``010515'';
0
ii. Revise the entries for ``065085'' and ``069043''; and
0
iii. Add in numerical order an entry for ``086121''.
The revisions and additions read as follows:
Sec. 510.600 Names, addresses, and drug labeler codes of sponsors of
approved applications.
* * * * *
(c) * * *
(1) * * *
------------------------------------------------------------------------
Drug labeler
Firm name and address code
------------------------------------------------------------------------
* * * * * * *
Anivive Lifesciences, Inc., 3250 Airflite Way, Suite 086121
400, Long Beach, CA 90807..............................
* * * * * * *
Cronus Pharma Specialities India Private Ltd., Sy No-99/ 069043
1, M/s GMR Hyderabad Aviation SEZ Ltd., Mamidipalli
Village, Shamshabad Mandal, Ranga Reddy, Hyderabad,
Telangana, 501218, India...............................
* * * * * * *
Piramal Pharma Ltd., Ground Floor, Piramal Ananta, 065085
Agastya Corporate Park, Mumbai, Maharashtra, 400070,
India..................................................
[[Page 57996]]
* * * * * * *
------------------------------------------------------------------------
(2) * * *
------------------------------------------------------------------------
Drug labeler code Firm name and address
------------------------------------------------------------------------
* * * * * * *
065085.................. Piramal Pharma Ltd., Ground Floor, Piramal
Ananta, Agastya Corporate Park, Mumbai,
Maharashtra, 400070, India
* * * * * * *
069043.................. Cronus Pharma Specialities India Private Ltd.,
Sy No-99/1, M/s GMR Hyderabad Aviation SEZ
Ltd., Mamidipalli Village, Shamshabad Mandal,
Ranga Reddy, Hyderabad, Telangana, 501218,
India
* * * * * * *
086121.................. Anivive Lifesciences, Inc., 3250 Airflite Way,
Suite 400, Long Beach, CA 90807
* * * * * * *
------------------------------------------------------------------------
PART 516--NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES
0
3. The authority citation for part 516 continues to read as follows:
Authority: 21 U.S.C. 360ccc, 360ccc-2, 371.
0
4. Add Sec. 516.1858 to subpart E to read as follows:
Sec. 516.1858 Potassium bromide.
(a) Specifications. Each chewable tablet contains 250 or 500
milligrams (mg) potassium bromide.
(b) Sponsor. See No. 055246 in Sec. 510.600(c) of this chapter.
(c) Conditions of use--(1) Amount. Administer 25 to 68 mg per
kilogram (11 to 31 mg per pound) of body weight once daily. The dosage
can be divided and should be adjusted to clinical response.
(2) Indications for use. For the control of seizures associated
with idiopathic epilepsy in dogs.
(3) Limitations. Federal law restricts this drug to use by or on
the order of a licensed veterinarian. It is a violation of Federal law
to use this product other than as directed in the labeling.
0
5. Add Sec. 516.2980 to subpart E to read as follows:
Sec. 516.2980 Verdinexor.
(a) Specifications. Each tablet contains 2.5, 10, or 50 milligrams
(mg) verdinexor.
(b) Sponsor. See No. 086121 in Sec. 510.600(c) of this chapter.
(c) Conditions of use--(1) Amount. Administer verdinexor tablets
orally at an initial dose of 1.25 mg per kilogram (mg/kg) of body
weight twice per week with at least 72 hours between doses. If
tolerated after 2 weeks, increase the dose to 1.5 mg/kg twice per week
with at least 72 hours between doses.
(2) Indications for use. For the treatment of lymphoma in dogs.
(3) Limitations. Federal law restricts this drug to use by or on
the order of a licensed veterinarian. It is a violation of Federal law
to use this product other than as directed in the labeling.
PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
0
6. The authority citation for part 520 continues to read as follows:
Authority: 21 U.S.C. 360b.
0
7. In Sec. 520.441, revise paragraph (b)(1) to read as follows:
Sec. 520.441 Chlortetracycline powder.
* * * * *
(b) * * *
(1) Nos. 000010, 054771, and 069254 for use as in paragraph (d) of
this section.
* * * * *
0
8. In Sec. 520.455, revise the section heading and paragraph (b) to
read as follows:
Sec. 520. 455 Clomipramine.
* * * * *
(b) Sponsors. See Nos. 051311 and 086039 in Sec. 510.600(c) of
this chapter.
* * * * *
0
9. In Sec. 520.905c, revise paragraph (e)(2) to read as follows:
Sec. 520.905c Fenbendazole paste.
* * * * *
(e) * * *
(2) Beef and dairy cattle--(i) Amount. Administer orally 2.3 mg/lb
(5 mg/kg) body weight.
(ii) Indications for use. For the treatment and control of:
Lungworms: Adult (Dictyocaulus viviparus); Stomach worms: Adult brown
stomach worms (Ostertagia ostertagi), adult and fourth-stage larvae
barberpole worms (Haemonchus contortus), fourth-stage larvae barberpole
worms (H. placei), and adult and fourth-stage larvae small stomach
worms (Trichostrongylus axei); Intestinal worms (adult and fourth-stage
larvae): Hookworms (Bunostomum phlebotomum), thread-necked intestinal
worms (Nematodirus helvetianus), small intestinal worms (Cooperia
punctata and C. oncophora), bankrupt worms (Trichostrongylus
colubriformis), and nodular worms (Oesophagostomum radiatum).
(iii) Limitations. Milk taken during treatment and for 96 hours
after the last treatment must not be used for human consumption. Cattle
must not be slaughtered for human consumption within 8 days following
last treatment with this drug product. Not for use in beef calves less
than 2 months of age, dairy calves, and veal calves. A withdrawal
period has not been established for this product in preruminating
calves.
0
10. In Sec. 520.1189, revise paragraph (b) to read as follows:
Sec. 520.1189 Itraconazole.
* * * * *
(b) Sponsor. See No. 051311 in Sec. 510.600(c) of this chapter.
* * * * *
0
11. In Sec. 520.1248, revise paragraphs (b) and (c)(1) to read as
follows:
Sec. 520.1248 Levothyroxine.
* * * * *
[[Page 57997]]
(b) Sponsors. See Nos. 059051 and 061690 in Sec. 510.600(c) of
this chapter.
(c) * * *
(1) Amount. Administer by mouth as follows:
(i) No. 061690: 0.1 mg/10 pounds (lb) body weight (0.022 mg/
kilogram (kg)) as a single dose every 24 hours or as a divided dose
every 12 hours.
(ii) No. 059051: 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) body weight
twice daily.
* * * * *
0
12. In Sec. 520.1510, revise paragraph (b)(1) to read as follows:
Sec. 520. 1510 Nitenpyram.
* * * * *
(b) * * *
(1) No. 021091 for use as in paragraphs (d)(1)(i)(A),
(d)(1)(ii)(A), and (d)(2) of this section.
* * * * *
0
13. In Sec. 520.1696a, revise paragraph (b) to read as follows:
Sec. 520.1696a Penicillin G powder.
* * * * *
(b) Sponsors. See Nos. 016592, 042791, 054771, 061133, and 076475
in Sec. 510.600(c) of this chapter.
* * * * *
0
14. In Sec. 520.2090, revise paragraph (c)(2) to read as follows:
Sec. 520.2090 Sarolaner, moxidectin, and pyrantel.
* * * * *
(c) * * *
(2) Indications for use. For the prevention of heartworm disease
caused by Dirofilaria immitis and for the treatment and control of
roundworm (immature adult and adult Toxocara canis and adult Toxascaris
leonina) and adult hookworm (Ancylostoma caninum and Uncinaria
stenocephala) infections. Kills adult fleas (Ctenocephalides felis) and
is indicated for the treatment and prevention of flea infestations, and
the treatment and control of tick infestations with Amblyomma
americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick),
Dermacentor variabilis (American dog tick), Ixodes scapularis (black-
legged tick), and Rhipicephalus sanguineus (brown dog tick) for 1 month
in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds
or greater.
* * * * *
0
15. In Sec. 520.2645, revise paragraph (d)(2) to read as follows:
Sec. 520.2645 Tylvalosin.
* * * * *
(d) * * *
(2) Indications for use. For control of porcine proliferative
enteropathy (PPE) associated with Lawsonia intracellularis infection in
groups of swine intended for slaughter in buildings experiencing an
outbreak of PPE; and for control of swine respiratory disease (SRD)
associated with Bordetella bronchiseptica, Haemophilus parasuis,
Pasteurella multocida, Streptococcus suis, and Mycoplasma hyopneumoniae
in groups of swine intended for slaughter in buildings experiencing an
outbreak of SRD.
* * * * *
PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
0
16. The authority citation for part 522 continues to read as follows:
Authority: 21 U.S.C. 360b.
0
17. In Sec. 522.90c, revise paragraph (b) to read as follows:
Sec. 522.90c Ampicillin sodium.
* * * * *
(b) See Nos. 042791 and 054771 in Sec. 510.600(c) of this chapter.
* * * * *
0
18. In Sec. 522.558, revise paragraphs (b)(1) and to read as follows:
Sec. 522.558 Dexmedetomidine.
* * * * *
(b) * * *
(1) Nos. 026637 and 059399 for use of product described in
paragraph (a)(2) of this section.
* * * * *
0
19. In Sec. 522.970, revise paragraph (b)(1) and add paragraph (b)(3)
to read as follows:
Sec. 522.970 Flunixin.
* * * * *
(b) * * *
(1) See Nos. 000061, 055529, 058198, and 061133 for use as in
paragraph (e) of this section.
* * * * *
(3) See No. 016592 for use as in paragraphs (e)(1) and (e)(2) of
this section.
* * * * *
0
20. In Sec. 522.1193, revise paragraphs (b) and (e)(2) and (3) to read
as follows:
Sec. 522.1193 Ivermectin and clorsulon.
* * * * *
(b) Sponsors. See Nos. 000010, 055529, 058005, 061133, and 061651
in Sec. 510.600(c) of this chapter.
* * * * *
(e) * * *
(2) Indications for use. For the treatment and control of
gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus
placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata,
Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C.
punctata, C. pectinata, Oesophagostomum radiatum, Nematodirus
helvetianus (adults only), N. spathiger (adults only), Bunostomum
phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus
viviparus); liver flukes (adults only) (Fasciola hepatica); cattle
grubs (parasitic stages) (Hypoderma bovis, H. lineatum); sucking lice
(Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus);
mange mites (cattle scab) (Psoroptes ovis (syn. P. communis var.
bovis), Sarcoptes scabiei var. bovis); and for control of infections of
D. viviparus and O. radiatum for 28 days after treatment; O. ostertagi,
T. axei, and C. punctata for 21 days after treatment; and H. placei and
C. oncophora for 14 days after treatment.
(3) Limitations. Do not treat cattle within 21 days of slaughter.
Because a withdrawal time in milk has not been established, do not use
in female dairy cattle of breeding age. A withdrawal period has not
been established for this product in preruminating calves. Do not use
in calves to be processed for veal.
0
21. In Sec. 522.1225, revise paragraph (b) to read as follows:
Sec. 522.1225 Ketoprofen.
* * * * *
(b) Sponsors. See Nos. 054771 and 061133 in Sec. 510.600(c) of
this chapter.
* * * * *
0
22. In Sec. 522.1696a, revise paragraph (d)(2)(iii) to read as
follows:
Sec. 522.1696a Penicillin G benzathine and penicillin G procaine
suspension.
* * * * *
(d) * * *
(2) * * *
(iii) Limitations. Not for use within 30 days of slaughter. For No.
016592: A withdrawal period has not been established for this product
in pre-ruminating calves. Do not use in calves to be processed for
veal.
0
23. In Sec. 522.2630, revise paragraphs (b) and (d)(1)(iii)(A) to read
as follows:
Sec. 522.2630 Tulathromycin.
* * * * *
(b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this
chapter.
(1) Nos. 054771, 058198, and 061133 for use of product described in
paragraph (a)(1) as in paragraphs (d)(1)(i), (d)(1)(ii),
(d)(1)(iii)(A), and (d)(2) of this section.
(2) No. 054771 for use of product described in paragraph (a)(2) as
in
[[Page 57998]]
paragraphs (d)(1)(i), (d)(1)(ii)(B), (d)(1)(iii)(B), and (d)(2) of this
section.
* * * * *
(d) * * *
(1) * * *
(iii) * * *
(A) Cattle intended for human consumption must not be slaughtered
within 18 days from the last treatment. This drug is not approved for
use in female dairy cattle 20 months of age or older, including dry
dairy cows. Use in these cattle may cause drug residues in milk and/or
in calves born to these cows. Federal law restricts this drug to use by
or on the order of a licensed veterinarian.
* * * * *
PART 526--INTRAMAMMARY DOSAGE FORM NEW ANIMAL DRUGS
0
24. The authority citation for part 526 continues to read as follows:
Authority: 21 U.S.C. 360b.
0
25. In Sec. 526.1696, revise paragraph (b) to read as follows:
Sec. 526.1696 Penicillin G procaine.
* * * * *
(b) See Nos. 042791 and 061133 in Sec. 510.600(c) of this chapter.
* * * * *
PART 556--TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
0
26. The authority citation for part 556 continues to read as follows:
Authority: 21 U.S.C. 342, 360b, 371.
0
27. In Sec. 556.275:
0
a. Revise paragraph (b)(1)(ii);
0
b. Remove paragraph (b)(1)(iii); and
0
c. Remove and reserve paragraphs (b)(3)(ii), (b)(4)(ii), and
(b)(5)(ii).
The revision reads as follows:
Sec. 556.275 Fenbendazole.
* * * * *
(b) * * *
(1) * * *
(ii) Milk: 0.22 ppm fenbendazole sulfoxide (marker residue).
* * * * *
PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
0
28. The authority citation for part 558 continues to read as follows:
Authority: 21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371.
0
29. In Sec. 558.76:
0
a. Revise paragraphs (a)(1) and (2) and (d)(1);
0
b. Redesignate paragraph (d)(2) as paragraph (d)(6); and
0
c. Add new paragraph (d)(2) and paragraphs (d)(3) through (5).
The revisions and additions read as follows:
Sec. 558.76 Bacitracin methylenedisalicylate.
(a) * * *
(1) Type A medicated articles containing feed grade bacitracin
methylenedisalicylate equivalent to 10, 25, 30, 40, 50, 60, or 75 grams
bacitracin per pound.
(2) Type A medicated article containing feed grade bacitracin
methylenedisalicylate equivalent to 50 grams bacitracin per pound.
* * * * *
(d) * * *
(1) Chickens--
------------------------------------------------------------------------
Bacitracin in grams per Indications for
ton use Limitations Sponsor
------------------------------------------------------------------------
(i) 4 to 50............ Broiler and Feed 054771
replacement continuously as 069254
chickens: For sole ration.
increased rate
of weight gain
and improved
feed efficiency.
(ii) 10 to 25.......... Laying hens: For Feed 054771
increased egg continuously as
production and sole ration for
improved feed the first 7
efficiency. months of egg
production.
(iii) 50............... Broiler and Feed 054771
replacement continuously as
chickens: As an sole ration.
aid in the
prevention of
necrotic
enteritis
caused or
complicated by
Clostridium
spp. or other
organisms
susceptible to
bacitracin.
(iv) 100 to 200........ Broiler and Feed 054771
replacement continuously as
chickens: As an sole ration.
aid in the Start at first
control of clinical signs
necrotic of disease.
enteritis Vary dosage
caused or based on
complicated by severity of
Clostridium infection.
spp. or other Administer
organisms continuously
susceptible to for 5 to 7 days
bacitracin. or as long as
clinical signs
persist, then
reduce
medication to
prevention
level (50 grams/
ton).
------------------------------------------------------------------------
(2) Turkeys--
------------------------------------------------------------------------
Bacitracin in grams per Indications for
ton use Limitations Sponsor
------------------------------------------------------------------------
(i) 4 to 50............ Growing turkeys: Feed 054771
For increased continuously as 069254
rate of weight sole ration.
gain and
improved feed
efficiency.
(ii) 200............... Growing turkeys: Feed 054771
As an aid in continuously as
the control of the sole ration.
transmissible
enteritis
complicated by
organisms
susceptible to
bacitracin
methylenedisali
cylate.
------------------------------------------------------------------------
(3) Swine--
------------------------------------------------------------------------
Bacitracin in grams per Indications for
ton use Limitations Sponsor
------------------------------------------------------------------------
(i) 10 to 30........... Growing and ................ 054771
finishing
swine: For
increased rate
of weight gain
and improved
feed efficiency.
[[Page 57999]]
(ii) 250............... Growing and Feed as the sole 054771
finishing ration. Feed
swine: For 250 grams per
control of ton of complete
swine dysentery feed on
(bloody scours) premises with a
associated with history of
Brachyspira swine
hyodysenteriae dysentery, but
in pigs up to where signs of
250 lbs body the disease
weight. have not yet
occurred or
following an
approved
treatment of
the disease
condition.
Diagnosis
should be
confirmed by a
veterinarian a
when results
are not
satisfactory.
(iii) 250.............. Pregnant sows: As the sole 054771
For control of ration. Feed to
clostridial sows from 14
enteritis days before
caused by through 21 days
Clostridium after farrowing
perfringens in on premises
suckling with a history
piglets. of clostridial
scours.
Diagnosis
should be
confirmed by a
veterinarian
when results
are not
satisfactory.
------------------------------------------------------------------------
(4) Cattle--
------------------------------------------------------------------------
Indications for
Bacitracin amount use Limitations Sponsor
------------------------------------------------------------------------
(i) 70 mg per head per Beef steers and Administer 054771
day. heifers fed in continuously 069254
confinement for throughout the
slaughter: For feeding period.
reduction in
the number of
liver
condemnations
due to
abscesses.
(ii) 250 mg per head Beef steers and Administer 054771
per day. heifers fed in continuously 069254
confinement for for 5 days then
slaughter: For discontinue for
reduction in subsequent 25
the number of days, repeat
liver the pattern
condemnations during the
due to feeding period.
abscesses.
------------------------------------------------------------------------
(5) Game birds--
------------------------------------------------------------------------
Bacitracin in grams per Indications for
ton use Limitations Sponsor
------------------------------------------------------------------------
(i) 4 to 50............ Growing Feed 054771
pheasants: For continuously as 069254
increased rate sole ration.
of weight gain
and improved
feed efficiency.
(ii) 5 to 20........... Growing quail: Feed 054771
For increased continuously as 069254
rate of weight sole ration to
gain and quail not over
improved feed 5 weeks of age.
efficiency in
quail not over
5 weeks of age.
(iii) 200.............. Growing quail: Feed 054771
For the continuously as
prevention of the sole ration.
ulcerative
enteritis in
growing quail
due to
Clostridium
colinum
susceptible to
bacitracin
methylenedisali
cylate.
------------------------------------------------------------------------
* * * * *
0
30. In Sec. 558.128, revise paragraphs (d)(4) and (e)(4) to read as
follows:
Sec. 558.128 Chlortetracycline.
* * * * *
(d) * * *
(4) Manufacture for use in free-choice feeds as in paragraph
(e)(4)(vi) of this section must conform to Sec. 510.455 of this
chapter.
* * * * *
(e) * * *
(4) * * *
----------------------------------------------------------------------------------------------------------------
Indications for
Chlortetracycline amount Combination in grams/ton use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
(i) to provide 70 mg/head/day... ............................... Growing cattle Feed to provide 054771
(over 400 lb): chlortetracycli 066104
For reduction ne at the rate 069254
of liver of 70 mg per
condemnation animal daily. A
due to liver withdrawal
abscesses. period has not
been
established in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal.
(ii) 5.83 to 14 g/ton to provide Melengestrol acetate, 0.25 to 2 Growing beef Melengestrol 054771
70 mg/head/day. g/ton to provide 0.25 to 0.5 heifers fed in acetate Type C
mg melengestrol acetate per confinement for top-dress
head per day. slaughter (over medicated feed
400 lb): For must be top
reduction of dressed onto or
the incidence mixed at
of liver feeding with
abscesses, the Type C
increased rate medicated feed
of weight gain, containing 5.83
improved feed to 14 g/ton
efficiency, and chlortetracycli
suppression of ne.
estrus (heat). Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58000]]
(iii) to provide 0.5 mg/lb of ............................... Beef cattle Feed to provide 054771
body weight daily. (over 700 lb): chlortetracycli 066104
For control of ne at the rate 069254
active of 0.5 mg per
infection of pound of body
anaplasmosis weight daily in
caused by beef cattle
Anaplasma under 700
marginale pounds.
susceptible to Withdraw 48
chlortetracycli hours prior to
ne. slaughter. To
sponsor Nos.
054771 and
069254: Zero
withdrawal time.
(iv) 33.33 to 50 g/ton to Melengestrol acetate, 0.5 to 2 Replacement beef Melengestrol 054771
provide 0.5 mg/lb of body g/ton to provide 0.5 mg heifers over acetate Type C
weight per day. melengestrol acetate per head 700 lb: For top-dress
per day. control of medicated feed
active must be top
infection of dressed onto or
anaplasmosis mixed at
caused by feeding with a
Anaplasma Type C
marginale medicated feed
susceptible to containing
chlortetracycli 33.33 to 50 g/
ne and for ton
suppression of chlortetracycli
estrus (heat). ne. Feeding a
Type C top-
dress medicated
feed containing
melengestrol
acetate shall
not exceed 24
days.
Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(v) 25 to 1,100 g/ton to provide Lasalocid, 30 to 600........... Pasture cattle Feed 054771
0.5 mg/lb of body weight daily. (slaughter, continuously on 069254
stocker, feeder a hand-fed
cattle, beef basis 0.5 mg
replacement chlortetracycli
heifers) over ne per lb. body
700 pounds: For weight per day
control of and not less
active than 60 mg or
infection of more than 300
anaplasmosis mg lasalocid
caused by per head daily
Anaplasma in at least 1
marginale pound of feed.
susceptible to Daily lasalocid
chlortetracycli intakes in
ne; and for excess of 200
increased rate mg/head/day in
of weight gain. pasture cattle
have not been
shown to be
more effective
than 200 mg
lasalocid/head/
day. Do not
allow horses or
other equines
access to feeds
containing
lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(vi) 25 to 1,100 g/ton to Lasalocid, 30 to 600; Replacement beef The melengestrol 054771
provide 0.5 mg/lb of body melengestrol acetate, 0.5 to 2 heifers on acetate Type C
weight daily. g/ton to provide 0.5 mg/head/ pasture over top-dress
day melengestrol acetate. 700 pounds: For medicated feed
control of must be top
active dressed onto or
infection of mixed at
anaplasmosis feeding with a
caused by Type C
Anaplasma medicated feed
marginale containing 25
susceptible to to 1,100 g/ton
chlortetracycli of
ne, increased chlortetracycli
rate of weight ne and 30 to
gain, and 600 g/ton
suppression of lasalocid to
estrus (heat). provide 0.5 mg
chlortetracycli
ne per lb body
weight per day
and not less
than 60 mg or
more than 300
mg lasalocid
per head per
day in at least
1 pound of
feed. Do not
exceed 24 days
of feeding. See
Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(vii) to provide 0.5 to 2.0 mg/ ............................... Beef cattle and In free-choice 054771
lb of body weight daily. nonlactating cattle feeds 069254
dairy cattle: such as feed
As an aid in blocks or salt-
the control of mineral mixes
active manufactured
infection of from approved
anaplasmosis Type A
caused by articles. See
Anaplasma paragraph
marginale (d)(4) of this
susceptible to section.
chlortetracycli
ne.
[[Page 58001]]
(viii) to provide 10 mg/lb of ............................... Calves, beef and Feed 054771
body weight daily. nonlactating approximately 066104
dairy cattle: 400 g/ton, 069254
For treatment varying with
of bacterial body weight and
enteritis feed
caused by consumption to
Escherichia provide 10 mg/
coli and lb per day.
bacterial Treat for not
pneumonia more than 5
caused by days. To
Pasteurella sponsor No.
multocida 054771 (NADAs
organisms 048-761 and 046-
susceptible to 699) and to
chlortetracycli sponsor No.
ne. 069254 (ANADA
200-510): May
be mixed in the
cattle's daily
ration or
administered as
a top-dress. In
feed including
milk replacers
withdraw 10
days prior to
slaughter. To
sponsor Nos.
054771 and
069254: Zero
withdrawal
time. See
paragraph
(d)(3) of this
section.
(ix) to provide 10 mg/lb of body ............................... Calves (up to A withdrawal 054771
weight daily. 250 lb): For period has not 066104
the treatment been 069254
of bacterial established for
enteritis this product in
caused by pre-ruminating
Escherichia calves. Do not
coli use in calves
susceptible to to be processed
chlortetracycli for veal.
ne.
(x) to provide 10 mg/lb of body Laidlomycin, 5................. Cattle fed in Feed 054771
weight daily. confinement for continuously at
slaughter: For a rate of 30 to
treatment of 75 mg
bacterial laidlomycin
enteritis propionate
caused by potassium per
Escherichia head per day
coli and for not more
bacterial than 5 days. A
pneumonia withdrawal
caused by period has not
Pasteurella been
multocida established for
organisms this product in
susceptible to pre-ruminating
chlortetracycli calves. Do not
ne; and for use in calves
increased rate to be processed
of weight and for veal. See
improved feed Sec.
efficiency. 558.305(d) of
this chapter.
Laidlomycin as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xi) to provide 10 mg/lb of body Laidlomycin, 5 to 10........... Cattle fed in Feed 054771
weight daily. confinement for continuously at
slaughter: For a rate of 30 to
treatment of 75 mg
bacterial laidlomycin
enteritis propionate
caused by potassium per
Escherichia head per day
coli and for not more
bacterial than 5 days. A
pneumonia withdrawal
caused by period has not
Pasteurella been
multocida established for
organisms this product in
susceptible to pre-ruminating
chlortetracycli calves. Do not
ne; and for use in calves
improved feed to be processed
efficiency. for veal. See
Sec.
558.305(d) of
this chapter.
Laidlomycin as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xii) 500 to 2,000 to provide 10 Lasalocid, 10 to 30............ Cattle fed in Feed 054771
mg/lb of body weight daily. confinement for continuously in 069254
slaughter: For complete feed
treatment of for not more
bacterial than 5 days to
enteritis provide 10 mg
caused by chlortetracycli
Escherichia ne per lb. body
coli and weight per day
bacterial and not less
pneumonia than 100 mg or
caused by more than 360
Pasteurella mg lasalocid
multocida per head per
organisms day. Do not
susceptible to allow horses or
chlortetracycli other equines
ne; and for access to feeds
improved feed containing
efficiency. lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58002]]
(xiii) to provide 10 mg/lb of Lasalocid, 25 to 30............ Cattle fed in Feed 054771
body weight daily. confinement for continuously in 069254
slaughter: For complete feed
treatment of for not more
bacterial than 5 days to
enteritis provide 10 mg
caused by chlortetracycli
Escherichia ne per lb. body
coli and weight per day
bacterial and not less
pneumonia than 250 mg or
caused by more than 360
Pasteurella mg lasalocid
multocida per head per
organisms day. Do not
susceptible to allow horses or
chlortetracycli other equines
ne; and for access to feeds
increased rate containing
of weight gain lasalocid. No
and improved withdrawal
feed efficiency. period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xiv) 500 to 4,000 to provide 10 Lasalocid, 30 to 600........... Pasture cattle Feed 054771
mg/lb of body weight daily. (slaughter, continuously on 069254
stocker, feeder a hand-fed
cattle, dairy basis for not
and beef more than 5
replacement days to provide
heifers): For 10 mg
treatment of chlortetracycli
bacterial ne per lb. body
enteritis weight per day
caused by and not less
Escherichia than 60 mg or
coli and more than 300
bacterial mg lasalocid
pneumonia per head per
caused by day in at least
Pasteurella 1 pound of
multocida feed. Daily
organisms lasalocid
susceptible to intakes in
chlortetracycli excess of 200
ne; and for mg/head/day in
increased rate pasture cattle
of weight gain. have not been
shown to be
more effective
than 200 mg
lasalocid/head/
day. Do not
allow horses or
other equines
access to feeds
containing
lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xv) 500 to 4,000 g/ton to Lasalocid, 30 to 600: Replacement The melengestrol 054771
provide 10 mg/lb of body weight Melengestrol acetate, 0.5 to 2 dairy heifers acetate Type C
daily. g/ton to provide 0.5 mg/head/ on pasture less top-dress
day melengestrol acetate. than 20 months medicated feed
of age and must be top
replacement dressed onto or
beef heifers on mixed at
pasture: For feeding with a
treatment of Type C
bacterial medicated feed
enteritis containing 500
caused by to 4,000 g/ton
Escherichia of
coli and chlortetracycli
bacterial ne and 30 to
pneumonia 600 g/ton
caused by lasalocid to
Pasteurella provide 10 mg
multocida chlortetracycli
organisms ne per lb body
susceptible to weight per day
chlortetracycli and not less
ne, increased than 60 mg or
rate of weight more than 300
gain, and mg lasalocid
suppression of per head per
estrus (heat). day in at least
1 pound of feed
for not more
than 5 days.
After
completing
feeding of this
combination,
continue
feeding a Type
C top-dress
medicated feed
containing
melengestrol
acetate alone
for a total
time not
exceeding 24
days of
feeding. See
Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58003]]
(xvi) 500 to 4,000 g/ton........ ............................... Calves, beef and Hand feed 054771
nonlactating continuously 069254
dairy cattle: for not more
For the than 5 days to
treatment of provide 10 mg/
bacterial lb body weight
enteritis per day. A
caused by withdrawal
Escherichia period has not
coli and been
bacterial established for
pneumonia this product in
caused by pre-ruminating
Pasteurella calves. Do not
multocida use in calves
susceptible to to be processed
chlortetracycli for veal. To
ne. sponsor No.
054771 under
NADA 046-699:
24-hour
withdrawal
period. To
sponsor No.
054771 under
NADA 048-761
and No. 069254
under ANADA 200-
510: Zero
withdrawal
period.
(xvii) 500 to 4,000 g/ton....... Decoquinate, 12.9 to 90.8...... Calves, beef and Feed at a rate 054771
non-lactating of 1g 069254
dairy cattle: chlortetracycli
For the ne per 100 lb
treatment of body weight/day
bacterial and 22.7 mg
enteritis decoquinate per
caused by 100 lb of body
Escherichia weight/day for
coli and not more than 5
bacterial days. When it
pneumonia is fully
caused by consumed,
Pasteurella resume feeding
multocida 22.7 mg
organisms decoquinate per
susceptible to 100 lb of body
chlortetracycli weight/day for
ne; and for the a total of 28
prevention of days to prevent
coccidiosis coccidiosis. A
caused by withdrawal
Eimeria bovis period has not
and E. zuernii. been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. Do
not feed to
animals
producing milk
for food.
Decoquinate as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xviii) 500 to 4,000 to provide Melengestrol acetate, 0.25 to 2 Growing beef Melengestrol 054771
10 mg per pound of body weight. g/ton to provide 0.25 to 0.5 heifers fed in acetate Type C
mg melengestrol acetate per confinement for top-dress
head per day. slaughter: For medicated feed
the treatment must be top
of bacterial dressed onto or
enteritis mixed at
caused by feeding with a
Escherichia Type C
coli and medicated feed
bacterial containing 500
pneumonia to 4,000 g/ton
caused by chlortetracycli
Pasteurella ne for not more
multocida than 5 days.
organisms After
susceptible to completing
chlortetracycli feeding of this
ne, increased combination,
rate of weight continue
gain, improved feeding a Type
feed C top-dress
efficiency, and medicated feed
suppression of containing
estrus (heat). melengestrol
acetate alone.
Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xix) 500 to 4,000 to provide 10 Melengestrol acetate, 0.5 to 2 Replacement Melengestrol 054771
mg per pound of body weight. g/ton to provide 0.5 mg dairy heifers acetate Type C
melengestrol acetate per head less than 20 top-dress
per day. months of age medicated feed
and replacement must be top
beef heifers: dressed onto or
For the mixed at
treatment of feeding with a
bacterial Type C
enteritis medicated feed
caused by containing 500
Escherichia to 4,000 g/ton
coli and chlortetracycli
bacterial ne for not more
pneumonia than 5 days.
caused by After
Pasteurella completing
multocida feeding of this
organisms combination,
susceptible to continue
chlortetracycli feeding a Type
ne, and for C top-dress
suppression of medicated feed
estrus (heat). containing
melengestrol
acetate alone
for a total
time not
exceeding 24
days. Use in
dairy heifers
less than 20
months of age
may cause drug
residues in
milk and/or in
calves born to
these cows. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal.
Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58004]]
(xx) 4,000 to 20,000 g/ton...... ............................... Calves, beef and Administer as a 054771
nonlactating top dress, 069254
dairy cattle: varying with
For the body weight and
treatment of feed
bacterial consumption, to
enteritis provide 10 mg/
caused by lb per day.
Escherichia Treat for not
coli and more than 5
bacterial days. A
pneumonia withdrawal
caused by period has not
Pasteurella been
multocida established for
organisms this product in
susceptible to pre-ruminating
chlortetracycli calves. Do not
ne. use in calves
to be processed
for veal.
(xxi) 4,000 to 20,000 g/ton..... Decoquinate, 90.8 to 535.7..... Calves, beef and Feed at a rate 054771
non-lactating of 1g 069254
dairy cattle: chlortetracycli
For the ne per 100 lb
treatment of body weight/day
bacterial and 22.7 mg
enteritis decoquinate per
caused by 100 lb of body
Escherichia weight/day for
coli and not more than 5
bacterial days. When it
pneumonia is fully
caused by consumed,
Pasteurella resume feeding
multocida 22.7 mg
organisms decoquinate per
susceptible to 100 lb of body
chlortetracycli weight/day for
ne; and for the a total of 28
prevention of days to prevent
coccidiosis coccidiosis. A
caused by withdrawal
Eimeria bovis period has not
and E. zuernii. been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. Do
not feed to
animals
producing milk
for food.
Decoquinate as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxii) 4,000 to 20,000 g/ton to Melengestrol acetate, 0.25 to 2 Growing beef Top dress 0.5 to 054771
provide 10 mg/lb of body weight g/ton to provide 0.25 to 0.5 heifers fed in 2 pounds of
per day. mg melengestrol acetate per confinement for this medicated
head per day. slaughter: For feed containing
the treatment both drugs onto
of bacterial or mix at
enteritis feeding with a
caused by non-medicated
Escherichia feed for not
coli and more than 5
bacterial days. After
pneumonia completing
caused by feeding of this
Pasteurella combination,
multocida continue
organisms feeding a Type
susceptible to C top-dress
chlortetracycli medicated feed
ne, and for containing
increased rate melengestrol
of weight gain, acetate alone.
improved feed A withdrawal
efficiency, and period has not
suppression of been
estrus (heat). established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal.
Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxiii) 4,000 to 20,000 g/ton to Melengestrol acetate, 0.5 to 2 Replacement Top dress 0.5 to 054771
provide 10 mg/lb of body weight g/ton to provide 0.5 mg dairy heifers 2 pounds of
per day. melengestrol acetate per head less than 20 this medicated
per day. months of age feed containing
and replacement both drugs onto
beef heifers: or mix at
For the feeding with a
treatment of non-medicated
bacterial feed for not
enteritis more than 5
caused by days. After
Escherichia completing
coli and feeding of this
bacterial combination,
pneumonia continue
caused by feeding a Type
Pasteurella C top-dress
multocida medicated feed
organisms containing
susceptible to melengestrol
chlortetracycli acetate alone
ne, and for for a total
suppression of time not
estrus (heat). exceeding 24
days. Use in
dairy heifers
less than 20
months of age
may cause drug
residues in
milk and/or in
calves born to
these cows. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal.
Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58005]]
(xxiv) to provide 350 mg/head/ ............................... Beef cattle: For Feed to provide 054771
day. control of chlortetracycli 066104
bacterial ne at the rate 069254
pneumonia of 350 mg per
associated with animal daily. A
shipping fever withdrawal
complex caused period has not
by Pasteurella been
spp. established for
susceptible to this product in
chlortetracycli pre-ruminating
ne. calves. Do not
use in calves
to be processed
for veal.
Withdrawal
periods: To
sponsor No.
054771 under
NADAs 046-699
and 049-287,
No. 066104
under NADA 092-
286, and No.
069254 under
NADA 048-480:
Withdraw 48
hours prior to
slaughter. To
sponsor No.
054771 under
NADA 048-761
and No. 069254
under NADA 138-
935 and ANADA
200-510: Zero
withdrawal
period.
(xxv) to provide 350 mg/head/day ............................... Beef cattle Feed to provide 054771
(under 700 lb): chlortetracycli 066104
For control of ne at the rate 069254
active of 350 mg per
infection of animal daily. A
anaplasmosis withdrawal
caused by period has not
Anaplasma been
marginale established for
susceptible to this product in
chlortetracycli pre-ruminating
ne. calves. Do not
use in calves
to be processed
for veal.
Withdrawal
periods: To
sponsor No.
054771 under
NADAs 046-699
and 049-287,
No. 066104
under NADA 092-
286, and No.
069254 under
NADA 048-480:
Withdraw 48
hours prior to
slaughter. To
sponsor No.
054771 under
NADA 048-761
and No. 069254
under NADA 138-
935 and ANADA
200-510: Zero
withdrawal
period.
(xxvi) 50 to 350 g/ton to Melengestrol acetate, 0.5 to 2 Replacement beef Melengestrol 054771
provide 350 mg/head/day. g/ton to provide 0.5 mg heifers under acetate Type C
melengestrol acetate per head 700 lb: For top-dress
per day. control of medicated feed
active must be top
infection of dressed or
anaplasmosis mixed at
caused by feeding with
Anaplasma the Type C
marginale medicated feed
susceptible to containing 50
chlortetracycli to 350 g/ton
ne and for chlortetracycli
suppression of ne for up to 24
estrus (heat). days of
feeding. Do not
exceed 24 days
of feeding.
Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxvii) 20 to 350 g/ton......... ............................... Beef cattle and Feed to provide 054771
replacement chlortetracycli 069254
dairy heifers: ne at the rate
For control of of 350 mg per
bacterial head per day.
pneumonia This drug is
associated with not approved
shipping fever for use in
complex caused female dairy
by Pasteurella cattle 20
spp. months of age
susceptible to or older,
chlortetracycli including dry
ne. dairy cows. Use
in these cattle
may cause drug
residues in
milk and/or in
calves born to
these cows. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. To
sponsor No.
054771 under
NADA 048-761
and No. 069254
under ANADA 200-
510: Zero
withdrawal
period.
(xxviii) 20 to 350 g/ton to Melengestrol acetate, 0.25 to 2 Growing beef Melengestrol 054771
provide 350 mg/head/day. g/ton to provide 0.25 to 0.5 heifers fed in acetate Type C
mg melengestrol acetate per confinement for top-dress
head per day. slaughter: For medicated feed
control of must be top
bacterial dressed onto or
pneumonia mixed at
associated with feeding with
shipping fever the Type C
complex caused medicated feed
by Pasteurella containing 20
spp. to 350 g/ton
susceptible to chlortetracycli
chlortetracycli ne.
ne, increased Chlortetracycli
rate of weight ne and
gain, improved melengestrol as
feed provided by No.
efficiency, and 054771 in Sec.
suppression of 510.600(c) of
estrus (heat). this chapter.
[[Page 58006]]
(xxix) 20 to 350 g/ton to Melengestrol acetate, 0.5 to 2 Replacement Melengestrol 054771
provide 350 mg/head/day. g/ton to provide 0.5 mg dairy heifers acetate Type C
melengestrol acetate per head less than 20 top-dress
per day. months of age medicated feed
and replacement must be top
beef heifers: dressed or
For control of mixed at
bacterial feeding with
pneumonia the Type C
associated with medicated feed
shipping fever containing 20
complex caused to 350 g/ton
by Pasteurella chlortetracycli
spp. ne. Use in
susceptible to dairy heifers
chlortetracycli less than 20
ne and months of age
suppression of may cause drug
estrus (heat). residues in
milk and/or in
calves born to
these cows. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal.
Chlortetracycli
ne and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxx) to provide 350 mg/head/day Laidlomycin, 5................. Cattle fed in Feed 054771
confinement for continuously at
slaughter: For a rate of 30 to
control of 75 mg
bacterial laidlomycin
pneumonia propionate
associated with potassium per
shipping fever head per day. A
complex caused withdrawal
by Pasteurella period has not
spp. been
susceptible to established for
chlortetracycli this product in
ne; and for pre-ruminating
increased rate calves. Do not
of weight and use in calves
improved feed to be processed
efficiency. for veal. See
Sec.
558.305(d) of
this chapter.
Laidlomycin as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxxi) to provide 350 mg/head/ Laidlomycin, 5 to 10........... Cattle fed in Feed 054771
day. confinement for continuously at
slaughter: For a rate of 30 to
control of 75 mg
bacterial laidlomycin
pneumonia propionate
associated with potassium per
shipping fever head per day. A
complex caused withdrawal
by Pasteurella period has not
spp. been
susceptible to established for
chlortetracycli this product in
ne; and for pre-ruminating
improved feed calves. Do not
efficiency. use in calves
to be processed
for veal. See
Sec.
558.305(d) of
this chapter.
Laidlomycin as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxxii) 25 to 42.2 g/ton to Lasalocid, 25 to 30............ Cattle under 700 Feed 054771
provide 350 mg/head/day. pounds fed in continuously in 069254
confinement for complete feed
slaughter: For at a rate of
control of 350 mg
active chlortetracycli
infection of ne and not less
anaplasmosis than 250 mg nor
caused by more than 360
Anaplasma mg lasalocid
marginale per head daily.
susceptible to Do not allow
chlortetracycli horses or other
ne; and for equines access
increased rate to feeds
of weight gain containing
and improved lasalocid. No
feed efficiency. withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxxiii) 25 to 42.2 g/ton to Lasalocid, 25 to 30............ Cattle fed in Feed 054771
provide 350 mg/head/day. confinement for continuously in 069254
slaughter: For complete feed
control of at a rate of
bacterial 350 mg
pneumonia chlortetracycli
associated with ne and not less
shipping fever than 250 mg nor
complex caused more than 360
by Pasteurella mg lasalocid
multocida per head daily.
organisms Do not allow
susceptible to horses or other
chlortetracycli equines access
ne; and for to feeds
increased rate containing
of weight gain lasalocid. No
and improved withdrawal
feed efficiency. period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58007]]
(xxxiv) 25 to 100 g/ton to Lasalocid, 10 to 30............ Cattle under 700 Feed 054771
provide 350 mg/head/day. pounds fed in continuously in 069254
confinement for complete feed
slaughter: For at a rate of
control of 350 mg
active chlortetracycli
infection of ne and not less
anaplasmosis than 100 mg nor
caused by more than 360
Anaplasma mg lasalocid
marginale per head daily.
susceptible to Do not allow
chlortetracycli horses or other
ne; and for equines access
improved feed to feeds
efficiency. containing
lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxxv) 25 to 100 g/ton to Lasalocid, 10 to 30............ Cattle fed in Feed 054771
provide 350 mg/head/day. confinement for continuously in 069254
slaughter: For complete feed
control of at a rate of
bacterial 350 mg
pneumonia chlortetracycli
associated with ne and not less
shipping fever than 100 mg nor
complex caused more than 360
by Pasteurella mg lasalocid
multocida per head daily.
organisms Do not allow
susceptible to horses or other
chlortetracycli equines access
ne; and for to feeds
improved feed containing
efficiency. lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxxvi) 25 to 700 to provide 350 Lasalocid, 30 to 600........... Pasture cattle Feed 054771
g/head/day. (slaughter, continuously on 069254
stocker, feeder a hand-fed
cattle, dairy basis at a rate
and beef of 350 mg
replacement chlortetracycli
heifers): For ne and not less
control of than 60 mg nor
bacterial more than 300
pneumonia mg lasalocid
associated with per head per
shipping fever day in at least
complex caused 1 pound of
by Pasteurella feed. Daily
multocida lasalocid
organisms intakes in
susceptible to excess of 200
chlortetracycli mg/head/day in
ne; and for pasture cattle
increased rate have not been
of weight gain. shown to be
more effective
than 200 mg
lasalocid/head/
day. Do not
allow horses or
other equines
access to feeds
containing
lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxxvii) 25 to 700 g/ton to Lasalocid, 30 to 600; Replacement beef The melengestrol 054771
provide 350 mg/head/day. melengestrol acetate, 0.5 to 2 heifers on acetate Type C
g/ton to provide 0.5 mg/head/ pasture: For top-dress
day melengestrol acetate. control of medicated feed
bacterial must be top
pneumonia dressed onto or
associated with mixed at
shipping fever feeding with a
complex caused Type C
by Pasteurella medicated feed
spp. containing 25
susceptible to to 700 g/ton of
chlortetracycli chlortetracycli
ne, increased ne and 30 to
rate of weight 600 g/ton
gain, and lasalocid to
suppression of provide 350 mg
estrus (heat). chlortetracycli
ne per head
daily and not
less than 60 mg
or more than
300 mg
lasalocid per
head daily in
at least 1
pound of feed.
Do not exceed
24 days of
feeding. See
Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58008]]
(xxxviii) 25 to 700 to provide Lasalocid, 30 to 600........... Pasture cattle Feed 054771
350 mg/head/day. (slaughter, continuously on 069254
stocker, feeder a hand-fed
cattle, beef basis at a rate
replacement of 350 mg
heifers) under chlortetracycli
700 pounds: For ne and not less
control of than 60 mg nor
active more than 300
infection of mg lasalocid
anaplasmosis per head per
caused by day in at least
Anaplasma 1 pound of
marginale feed. Daily
susceptible to lasalocid
chlortetracycli intakes in
ne; and for excess of 200
increased rate mg/head/day in
of weight gain. pasture cattle
have not been
shown to be
more effective
than 200 mg
lasalocid/head/
day. Do not
allow horses or
other equines
access to feeds
containing
lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xxxix) 25 to 700 g/ton to Lasalocid, 30 to 600; Replacement beef The melengestrol 054771
provide 350 mg/head/day. melengestrol acetate, 0.5 to 2 heifers on acetate Type C
g/ton to provide 0.5 mg/head/ pasture under top-dress
day melengestrol acetate. 700 pounds: For medicated feed
control of must be top
active dressed onto or
infection of mixed at
anaplasmosis feeding with a
caused by Type C
Anaplasma medicated feed
marginale containing 25
susceptible to to 700 g/ton of
chlortetracycli chlortetracycli
ne, increased ne and 30 to
rate of weight 600 g/ton
gain, and lasalocid to
suppression of provide 350 mg
estrus (heat). chlortetracycli
ne per head
daily and not
less than 60 mg
or more than
300 mg
lasalocid per
head daily in
at least 1
pound of feed.
Do not exceed
24 days of
feeding. See
Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xl) 25 to 2,800 to provide 350 Lasalocid, 30 to 181.8......... Beef cattle Hand feed 054771
mg/head/day. weighing under continuously at 069254
700 pounds: For a rate of 350
control of mg
active chlortetracycli
infection of ne and 1 mg
anaplasmosis lasalocid per
caused by 2.2 lb. body
Anaplasma weight daily to
marginale cattle with a
susceptible to maximum of 360
chlortetracycli mg of lasalocid
ne; and for the per head per
control of day. Do not
coccidiosis allow horses or
caused by other equines
Eimeria bovis access to feeds
and E. zuernii. containing
lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne and
lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xli) 25 to 2,80 g/ton to Lasalocid, 30 to 181.8; Growing beef The melengestrol 054771
provide 350 mg/head/day. melengestrol acetate, 0.25 to heifers fed in acetate Type C
2 g/ton to provide 0.25 to 0.5 confinement for top-dress
mg/head/day melengestrol slaughter under medicated feed
acetate. 700 pounds: For must be top
control of dressed onto or
active mixed at
infection of feeding with a
anaplasmosis Type C
caused by medicated feed
Anaplasma containing 25
marginale to 2,800 g/ton
susceptible to of
chlortetracycli chlortetracycli
ne, control of ne and 30 to
coccidiosis 181.8 g/ton
caused by lasalocid to
Eimeria bovis provide 350 mg
and E. zuernii, chlortetracycli
increased rate ne per head per
of weight gain, day and 1 mg
improved feed lasalocid per
efficiency, and 2.2 lb. of body
suppression of weight daily
estrus (heat). with a maximum
of 360 mg
lasalocid per
head per day.
See Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58009]]
(xlii) 25 to 2,800 to provide Lasalocid, 30 to 181.8......... Beef cattle Hand feed 054771
350 mg/head/day. weighing up to continuously at 069254
800 pounds: For a rate of 350
control of mg
bacterial chlortetracycli
pneumonia ne and 1 mg
associated with lasalocid per
shipping fever 2.2 lb. body
complex caused weight daily to
by Pasteurella cattle with a
spp. maximum of 360
susceptible to mg of lasalocid
chlortetracycli per head per
ne; and for the day. Do not
control of allow horses or
coccidiosis other equines
caused by access to feeds
Eimeria bovis containing
and E. zuernii. lasalocid. No
withdrawal
period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xliii) 25 to 2,800 g/ton to Lasalocid, 30 to 181.8; Growing beef The melengestrol 054771
provide 350 mg/head/day. melengestrol acetate, 0.25 to heifers fed in acetate Type C
2 g/ton to provide 0.25 to 0.5 confinement for top-dress
mg/head/day melengestrol slaughter up to medicated feed
acetate. 800 pounds: For must be top
control of dressed onto or
bacterial mixed at
pneumonia feeding with a
associated with Type C
shipping fever medicated feed
complex caused containing 25
by Pasteurella to 2,800 g/ton
spp. of
susceptible to chlortetracycli
chlortetracycli ne and 30 to
ne, control of 181.8 g/ton
coccidiosis lasalocid to
caused by provide 350 mg
Eimeria bovis chlortetracycli
and E. zuernii, ne per head
increased rate daily and 1 mg
of weight gain, lasalocid per
improved feed 2.2 lb. of body
efficiency, and weight daily
suppression of with a maximum
estrus (heat). of 360 mg
lasalocid per
head per day.
See Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xliv) 25 to 2,800 g/ton to Lasalocid, 30 to 181.8; Replacement beef The melengestrol 054771
provide 350 mg/head/day. melengestrol acetate, 0.5 to 2 heifers up to acetate Type C
g/ton to provide 0.5 mg/head/ 800 pounds: For top-dress
day melengestrol acetate. control of medicated feed
bacterial must be top
pneumonia dressed onto or
associated with mixed at
shipping fever feeding with a
complex caused Type C
by Pasteurella medicated feed
spp. containing 25
susceptible to to 2,800 g/ton
chlortetracycli of
ne, control of chlortetracycli
coccidiosis ne and 30 to
caused by 181.8 g/ton
Eimeria bovis lasalocid to
and E. zuernii, provide 350 mg
and suppression chlortetracycli
of estrus ne per head
(heat). daily and 1 mg
lasalocid per
2.2 lb. of body
weight daily
with a maximum
of 360 mg
lasalocid per
head per day.
Do not exceed
24 days of
feeding. See
Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xlv) 500 to 4,000 to provide 10 Lasalocid, 30 to 181.8......... Cattle weighing Hand feed 054771
mg/head/day. up to 800 continuously 069254
pounds: For the for not more
treatment of than 5 days at
bacterial a rate of 10 mg
enteritis chlortetracycli
caused by ne and 1 mg
Escherichia lasalocid per
coli and 2.2 lb. body
bacterial weight daily to
pneumonia cattle with a
caused by maximum of 360
Pasteurella mg of lasalocid
multocida per head per
susceptible to day. Do not
chlortetracycli allow horses or
ne; and for the other equines
control of access to feeds
coccidiosis containing
caused by lasalocid. No
Eimeria bovis withdrawal
and E. zuernii. period is
required. A
withdrawal
period has not
been
established for
this product in
pre-ruminating
calves. Do not
use in calves
to be processed
for veal. See
Sec.
558.311(d) of
this chapter.
Lasalocid as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
[[Page 58010]]
(xlvi) 500 to 4,000 g/ton to Lasalocid, 30 to 181.8; Growing beef The melengestrol 054771
provide 10 mg/lb of body weight melengestrol acetate, 0.25 to heifers fed in acetate Type C
daily. 2 g/ton to provide 0.25 to 0.5 confinement for top-dress
mg/head/day melengestrol slaughter up to medicated feed
acetate. 800 pounds: For must be top
the treatment dressed onto or
of bacterial mixed at
enteritis feeding with a
caused by Type C
Escherichia medicated feed
coli and containing 500
bacterial to 4,000 g/ton
pneumonia of
caused by chlortetracycli
Pasteurella ne and 30 to
multocida 181.8 g/ton
organisms lasalocid to
susceptible to provide 10 mg
chlortetracycli chlortetracycli
ne, control of ne per lb of
coccidiosis body weight per
caused by day and 1 mg
Eimeria bovis lasalocid per
and E. zuernii, 2.2 lb of body
increased rate weight per day
of weight gain, with a maximum
improved feed of 360 mg
efficiency, and lasalocid per
suppression of head per day
estrus (heat). for not more
than 5 days of
feeding. After
completing
feeding of this
combination,
continue
feeding a Type
C top-dress
medicated feed
containing
melengestrol
acetate alone.
See Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
(xlvii) 500 to 4,000 g/ton to Lasalocid, 30 to 181.8; Replacement The melengestrol 054771
provide 10 mg/lb of body weight melengestrol acetate, 0.5 to 2 dairy heifers acetate Type C
daily. g/ton to provide 0.5 mg/head/ up to 800 top-dress
day melengestrol acetate. pounds and less medicated feed
than 20 months must be top
of age and dressed onto or
replacement mixed at
beef heifers up feeding with a
to 800 pounds: Type C
For the medicated feed
treatment of containing 500
bacterial to 4,000 g/ton
enteritis of
caused by chlortetracycli
Escherichia ne and 30 to
coli and 181.8 g/ton
bacterial lasalocid to
pneumonia provide 10 mg
caused by chlortetracycli
Pasteurella ne per lb of
multocida body weight per
organisms day and 1 mg
susceptible to lasalocid per
chlortetracycli 2.2 lb of body
ne, control of weight per day
coccidiosis with a maximum
caused by of 360 mg
Eimeria bovis lasalocid per
and E. zuernii, head per day
and suppression for not more
of estrus than 5 days.
(heat). After
completing
feeding of this
combination,
continue
feeding a Type
C top-dress
medicated feed
containing
melengestrol
acetate alone.
See Sec.
558.311(d) of
this chapter.
Chlortetracycli
ne, lasalocid,
and
melengestrol as
provided by No.
054771 in Sec.
510.600(c) of
this chapter.
----------------------------------------------------------------------------------------------------------------
* * * * *
0
31. In Sec. 558.342, revise paragraph (e)(1)(iv) to read as follows:
Sec. 558.342 Melengestrol.
* * * * *
(e) * * *
(1) * * *
----------------------------------------------------------------------------------------------------------------
Melengestrol acetate in Indications for
mg/head/day Combination in mg/head/day use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
* * * * * * *
(iv) 0.25 to 0.5.......... Monensin, 10 to 40......... Heifers fed in Add at the rate of 016592
confinement for 0.5 to 2.0 lb/ 045771
slaughter: For head/day a 058198
increased rate of medicated feed
weight gain, (liquid or dry)
improved feed containing 0.125
efficiency, and to 1.0 mg
suppression of melengestrol
estrus (heat); acetate/lb to a
and for the feed containing
prevention and 10 to 40 g of
control of monensin per ton
coccidiosis due to provide 0.25
to Eimeria bovis to 0.5 mg
and E. zuernii. melengestrol
acetate/head/day
and 0.14 to 0.42
mg monensin/lb
body weight,
depending on
severity of
coccidiosis
challenge, up to
480 mg monensin/
head/day. See
Sec. 558.355(d)
of this chapter.
Monensin as
provided by No.
016592 or 058198;
melengestrol
acetate as
provided by No.
016952, 054771,
or 058198 in Sec.
510.600(c) of
this chapter.
[[Page 58011]]
* * * * * * *
----------------------------------------------------------------------------------------------------------------
* * * * *
0
32. In Sec. 558.355, revise paragraphs (b)(2), (f)(2)(ii), (f)(3), and
(f)(4)(i) and (ii), remove paragraph (f)(4)(v), redesignate paragraph
(f)(4)(vi) as paragraph (f)(4)(v) and revise it, and revise paragraphs
(f)(6)(i) and (f)(7)(viii)
The revisions read as follows:
Sec. 558.355 Monensin.
* * * * *
(b) * * *
(2) No. 016592 for use of a Type A medicated article containing
90.7 grams monensin, USP, per pound as in paragraphs (f)(3), (f)(4)(v),
and (f)(6) of this section.
* * * * *
(f) * * *
(2) * * *
----------------------------------------------------------------------------------------------------------------
Combination in grams/
Monensin in grams/ton ton Indications for use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
* * * * * * *
(ii) 54 to 90.............. Bacitracin Growing turkeys: For Feed continuously as 058198
methylenedisalicyla the prevention of the sole ration. 069254
te, 4 to 50. coccidiosis caused The optimum level
by Eimeria depends upon the
adenoeides, E. severity of
meleagrimitis, and coccidiosis
E. gallopavonis, exposure. Do not
and for increased allow horses, other
rate of weight gain equines, mature
and improved feed turkeys, or guinea
efficiency. fowl access to feed
containing
monensin. Ingestion
of monensin by
horses and guinea
fowl has been
fatal. Some strains
of turkey coccidia
may be monensin
tolerant or
resistant. Monensin
may interfere with
development of
immunity to turkey
coccidiosis.
Bacitracin
methylenedisalicyla
te as provided by
No. 054771 or
069254 in Sec.
510.600(c) of this
chapter.
* * * * * * *
----------------------------------------------------------------------------------------------------------------
(3) * * *
------------------------------------------------------------------------
Indications for
Monensin in grams/ton use Limitations Sponsor
------------------------------------------------------------------------
(i) 5 to 40............ Growing beef Feed 016592
steers and continuously 058198
heifers fed in in complete
confinement for feed at a rate
slaughter: For of 50 to 480
improved feed milligrams of
efficiency. monensin per
head per day.
No additional
improvement in
feed
efficiency has
been shown
from feeding
monensin at
levels greater
than 30 grams
per ton (360
milligrams per
head per day).
See special
labeling
considerations
in paragraph
(d) of this
section.
(ii) 10 to 40.......... Growing beef Feed at a rate 016592
steers and of 0.14 to 058198
heifers fed in 0.42 milligram
confinement for per pound of
slaughter: For body weight
prevention and per day,
control of depending upon
coccidiosis due the severity
to Eimeria of challenge,
bovis and E. up to maximum
zuernii. of 480
milligrams per
head per day.
See special
labeling
considerations
in paragraph
(d) of this
section.
(iii) 10 to 200........ Calves excluding Feed at a rate 016592
veal calves: of 0.14 to 1.0 058198
For prevention milligram
and control of monensin per
coccidiosis due pound of body
to Eimeria weight per
bovis and E. day, depending
zuernii. upon the
severity of
challenge, up
to maximum of
200 milligrams
per head per
day. See
special
labeling
considerations
in paragraph
(d) of this
section.
(iv) 11 to 22.......... Dairy cows: For Feed 016592
increased milk continuously 058198
production to dry and
efficiency lactating
(production of dairy cows in
marketable a total mixed
solids- ration
corrected milk (``complete
per unit of feed''). See
feed intake). special
labeling
considerations
in paragraph
(d) of this
section.
(v) 11 to 400.......... Dairy cows: For Feed 016592
increased milk continuously 058198
production to dry and
efficiency lactating
(production of dairy cows in
marketable a component
solids- feeding system
corrected milk (including top
per unit of dress). The
feed intake). Type C
medicated feed
must be fed in
a minimum of 1
lb of feed to
provide 185 to
660 mg/head/
day monensin
to lactating
cows or 115 to
410 mg/head/
day monensin
to dry cows.
See special
labeling
considerations
in paragraph
(d) of this
section.
[[Page 58012]]
(vi) 15 to 400......... Growing beef For increased 016592
steers and rate of weight 058198
heifers on gain, feed at
pasture a rate of 50
(stocker, to 200
feeder, and milligrams
slaughter) or monensin per
in a dry lot head per day
and replacement in not less
beef and dairy than 1 pound
heifers: For of feed or,
increased rate after the 5th
of weight gain, day, feed at a
and for rate of 400
prevention and milligrams per
control of head per day
coccidiosis due every other
to Eimeria day in not
bovis and E. less than 2
zuernii. pounds of
feed. For
prevention and
control of
coccidiosis,
feed at a rate
of 0.14 to
0.42 milligram
per pound of
body weight
per day,
depending on
severity of
challenge, up
to 200
milligrams per
head per day.
During first 5
days of
feeding,
cattle should
receive no
more than 100
milligrams per
day in not
less than 1
pound of feed.
See special
labeling
considerations
in paragraph
(d) of this
section.
(vii) 25 to 400........ Beef cows: For Feed as 016592
improved feed supplemental 058198
efficiency when feed, either
receiving hand-fed in a
supplemental minimum of 1
feed, and for pound of feed
the prevention or mixed in a
and control of total ration.
coccidiosis due For improved
to Eimeria feed
bovis and E. efficiency,
zuernii. feed
continuously
at a rate of
50 to 200
milligrams
monensin per
head per day.
For prevention
and control of
coccidiosis,
feed at a rate
of 0.14 to
0.42 milligram
per pound of
body weight
per day,
depending upon
severity of
challenge, up
to a maximum
of 200
milligrams per
head per day.
During first 5
days of
feeding,
cattle should
receive no
more than 100
milligrams per
head per day
in not less
than 1 pound
of feed. See
special
labeling
considerations
in paragraph
(d) of this
section.
------------------------------------------------------------------------
(4) * * *
----------------------------------------------------------------------------------------------------------------
Monensin amount Indications for use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 150 milligrams per pound of protein- Growing beef steers and Provide 50 to 200 012286
mineral block (0.033%). heifers on pasture milligrams of monensin
(stocker, feeder, and (0.34 to 1.33 pounds
slaughter) and of block) per head per
replacement beef day, at least 1 block
heifers on pasture: For per 10 to 12 head of
increased rate of cattle. Roughage must
weight gain, and for be available at all
prevention and control times. Do not allow
of coccidiosis caused animals access to
by Eimeria bovis and E. other protein blocks,
zuernii in pasture salt or mineral, while
cattle which may being fed this
require supplemental product. See paragraph
feed. (d)(10)(i) of this
section.
(ii) 175 milligrams per pound of Growing beef steers and Provide 40 to 200 017800
protein-mineral block (0.038%). heifers on pasture milligrams of monensin
(stocker, feeder, and (0.25 to 1.13 pounds
slaughter): For or 4 to 18 ounces of
increased rate of block) per head per
weight gain. day, at least 1 block
per 4 head of cattle.
Do not allow cattle
access to salt or
mineral while being
fed this product.
Ingestion by cattle of
monensin at levels of
600 milligrams per
head per day and
higher has been fatal.
See paragraph
(d)(10)(i) of this
section.
* * * * * * *
(v) 1,620 grams per ton of mineral Growing beef steers and Feed at a rate of 50 to 016592
granules as specified in paragraph heifers on pasture 200 milligrams per 058198
(f)(4)(v)(A) of this section. (stocker, feeder, and head per day. During
slaughter) or in a dry the first 5 days of
lot and replacement feeding, cattle should
beef and dairy heifers: receive no more than
For increased rate of 100 milligrams per
weight gain, and for day. Do not feed
prevention and control additional salt or
of coccidiosis due to minerals. Do not mix
Eimeria bovis and E. with grain or other
zuernii. feeds. Monensin is
toxic to cattle when
consumed at higher
than approved levels.
Stressed and/or feed-
and/or water-deprived
cattle should be
adapted to the pasture
and to unmedicated
mineral supplement
before using the
monensin mineral
supplement.
----------------------------------------------------------------------------------------------------------------
(A) Specifications. Use as free-choice Type C medicated feed
formulated as mineral granules as follows:
------------------------------------------------------------------------
International
Ingredient Percent feed No.
------------------------------------------------------------------------
Monocalcium phosphate (21% phosphorus, 15% 29.49 6-01-082
calcium)....................................
Sodium chloride (salt)....................... 24.37 6-04-152
Dried cane molasses.......................... 20.0 4-04-695
Ground limestone (33% calcium) or calcium 13.75 6-02-632
carbonate (38% calcium).....................
[[Page 58013]]
Cane molasses................................ 3.0 4-04-696
Processed grain by-products (as approved by 5.0 ..............
AAFCO)......................................
Vitamin/trace mineral premix \1\............. 2.5 ..............
Monensin Type A article, 90.7 grams per pound 0.89 ..............
Antidusting oil.............................. 1.0 ..............
------------------------------------------------------------------------
\1\ Content of vitamin and trace mineral premixes may be varied.
However, they should be comparable to those used for other free-choice
feeds. Formulation modifications require FDA approval prior to
marketing. Selenium must comply with 21 CFR 573.920. Ethylenediamine
dihydroiodide should comply with FDA Compliance Policy Guide Sec.
651.100 (CPG 7125.18).
(B) [Reserved]
* * * * *
(6) * * *
------------------------------------------------------------------------
Indications for
Monensin in grams/ton use Limitations Sponsor
------------------------------------------------------------------------
(i) 20................. Goats maintained Feed 016592
in confinement: continuously. 058198
For the Do not feed to
prevention of lactating
coccidiosis goats. See
caused by paragraph
Eimeria (d)(11) of
crandallis, E. this section
christenseni, for provisions
and E. for monensin
ninakohlyakimov liquid Type C
ae. goat feeds.
* * * * * * *
------------------------------------------------------------------------
(7) * * *
(viii) Ractopamine as in Sec. 558.500.
* * * * *
0
33. In Sec. 558.500, revise paragraphs (e)(2)(ii), (iv), (v), and
(vii) to read as follows:
Sec. 558.500 Ractopamine.
* * * * *
(e) * * *
(2) * * *
----------------------------------------------------------------------------------------------------------------
Indications for
Ractopamine in grams/ton Combination in grams/ton use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
* * * * * * *
(ii) 8.2 to 24.6 to provide 70 Monensin 10 to 40 to provide Cattle fed in Feed 016592
to 430 mg/head/day. 0.14 to 0.42 mg monensin/lb of confinement continuously 054771
body weight, depending on for slaughter: as sole ration 058198
severity of coccidiosis For increased during the
challenge, up to 480 mg/head/ rate of weight last 28 to 42
day. gain, improved days on feed.
feed Not for
efficiency, animals
and prevention intended for
and control of breeding. See
coccidiosis special
due to Eimeria labeling
bovis and E. considerations
zuernii during in Sec.
the last 28 to 558.355(d) of
42 days on this chapter.
feed. Ractopamine as
provided by
No. 016592,
054771, or
058198;
monensin as
provided by
No. 016592 or
058198 in Sec.
510.600(c)
of this
chapter.
* * * * * * *
(iv) 9.8 to 24.6 to provide 90 Monensin 10 to 40 to provide Cattle fed in Feed 016592
to 430 mg/head/day. 0.14 to 0.42 mg monensin/lb of confinement continuously 054771
body weight, depending on for slaughter: as sole ration 058198
severity of coccidiosis For increased during the
challenge, up to 480 mg/head/ rate of weight last 28 to 42
day. gain, improved days on feed.
feed Not for
efficiency, animals
increased intended for
carcass breeding. See
leanness, and special
prevention and labeling
control of considerations
coccidiosis in Sec.
due to Eimeria 558.355(d) of
bovis and E. this chapter.
zuernii during Ractopamine as
the last 28 to provided by
42 days on No. 016592,
feed. 054771, or
058198;
monensin as
provided by
No. 016592 or
058198 in Sec.
510.600(c)
of this
chapter.
(v) 9.8 to 24.6 to provide 90 Monensin 10 to 40 to provide Heifers fed in Feed 016592
to 430 mg/head/day. 0.14 to 0.42 mg monensin/lb of confinement continuously 054771
body weight, depending on for slaughter: as sole ration 058198
severity of coccidiosis For increased during the
challenge, up to 480 mg/head/ rate of weight last 28 to 42
day, plus melengestrol acetate gain, improved days on feed.
to provide 0.25 to 0.5 mg/head/ feed Not for
day. efficiency, animals
increased intended for
carcass breeding. See
leanness, special
prevention and labeling
control of considerations
coccidiosis in Sec. Sec.
due to Eimeria 558.342(d)
bovis and E. and 558.355(d)
zuernii, and of this
suppression of chapter.
estrus (heat) Ractopamine as
during the provided by
last 28 to 42 No. 016592,
days on feed. 054771, or
058198;
monensin as
provided by
No. 016592 or
058198;
melengestrol
acetate as
provided by
No. 016592,
054771 or
058198 in Sec.
510.600(c)
of this
chapter.
[[Page 58014]]
* * * * * * *
(vii) Not to exceed 800; to Monensin 10 to 40 to provide Cattle fed in Top dress 016592
provide 70 to 400 mg/head/day. 0.14 to 0.42 mg monensin/lb of confinement ractopamine at 054771
body weight, depending on for slaughter: a minimum of 058198
severity of coccidiosis For increased 1.0 lb/head/
challenge, up to 480 mg/head/ rate of weight day of
day. gain, improved medicated feed
feed continuously
efficiency, during the
and prevention last 28 to 42
and control of days on feed.
coccidiosis Not for
due to Eimeria animals
bovis and E. intended for
zuernii during breeding. See
the last 28 to special
42 days on labeling
feed. considerations
in Sec.
558.355(d) of
this chapter.
Ractopamine as
provided by
No. 016592,
054771, or
058198;
monensin as
provided by
No. 016592 or
058198 in Sec.
510.600(c)
of this
chapter.
* * * * * * *
----------------------------------------------------------------------------------------------------------------
* * * * *
0
34. In Sec. 558. 550, revise paragraphs (a), (b), (e)(1)(i), and
(e)(2)(i) to read as follows:
Sec. 558. 550 Salinomycin.
(a) Specifications. Type A medicated articles containing 30 or 60
grams of salinomycin sodium activity per pound.
(b) Sponsor. See No. 016592 in Sec. 510.600(c) of this chapter for
use as in paragraph (e) of this section.
* * * * *
(e) * * *
(1) * * *
----------------------------------------------------------------------------------------------------------------
Salinomycin in grams/ton Combination in grams/ton Indications for use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 40 to 60.............. ........................ Broiler, roaster, Feed continuously 016592
and replacement as sole ration. Do
(breeder and not feed to birds
layer) chickens: producing eggs for
For the prevention human consumption.
of coccidiosis May be fatal if
caused by Eimeria accidentally fed
tenella, E. to adult turkeys
necatrix, E. or horses.
acervulina, E.
maxima, E.
brunetti, and E.
mivati.
* * * * * * *
----------------------------------------------------------------------------------------------------------------
(2) * * *
----------------------------------------------------------------------------------------------------------------
Combination in grams per
Salinomycin in grams/ton ton Indications for use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 50.................... ........................ Quail: For the Feed continuously 016592
prevention of as sole ration. Do
coccidiosis caused not feed to birds
by Eimeria producing eggs for
dispersa and E. human consumption.
lettyae. May be fatal if
accidentally fed
to adult turkeys
or horses.
* * * * * * *
----------------------------------------------------------------------------------------------------------------
* * * * *
0
35. In Sec. 558.625, revise paragraphs (e)(2)(i) and (e)(2)(ix)
through (xiii) to read as follows:
Sec. 558.625 Tylosin.
* * * * *
(e) * * *
(2) * * *
----------------------------------------------------------------------------------------------------------------
Combination in
Tylosin grams/ton grams/ton Indications for use Limitations Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 8 to 10..................... ................... Beef cattle: For Feed continuously 016592
reduction of as the sole ration 054771
incidence of liver to provide 60 to 058198
abscesses caused 90 mg/head/day 066104
by Fusobacterium tylosin.
necrophorum and
Arcanobacterium
pyogenes.
[[Page 58015]]
* * * * * * *
(ix) 8 to 10.................... Monensin 10 to 40 Heifers fed in Feed continuously 016592
plus melengestrol confinement for as sole ration to 054771
0.25 to 2.0. slaughter: For heifers at a rate 058198
reduction of of 0.5 to 2 pounds
incidence of liver per head per day
abscesses caused to provide 0.25 to
by Fusobacterium 0.5 mg/head/day
necrophorum and melengestrol
Arcanobacterium acetate and 0.14
pyogenes; for to 0.42 mg
prevention and monensin/lb body
control of weight per day,
coccidiosis caused depending on the
by Eimeria bovis severity of the
and E. zuernii; coccidiosis
and for increased challenge, up to
rate of weight 480 mg/head/day
gain, improved and 60 to 90 mg/
feed efficiency, head/day tylosin.
and suppression of The melengestrol
estrus (heat). acetate portion of
this Type C
medicated feed
must be mixed into
the complete feed
containing 10 to
40 g/ton monensin
and 8 to 10 g/ton
tylosin at feeding
into the amount of
complete feed
consumed by an
animal per day. A
withdrawal time
has not been
established for
pre-ruminating
calves. Do not use
in calves to be
processed for
veal. See Sec.
Sec. 558.342(d)
and 558.355(d) of
this chapter.
Tylosin provided
by No. 016592 or
058198; monensin
as provided by No.
016592 or 058198;
melengestrol
provided by No.
016592, 054771, or
058198 in Sec.
510.600(c) of this
chapter.
(x) 8 to 10..................... Monensin 10 to 40 Cattle fed in Feed continuously 016592
plus ractopamine confinement for as sole ration to 054771
8.2 to 24.6. slaughter: For provide 70 to 430 058198
reduction of mg/head/day
incidence of liver ractopamine and
abscesses caused 0.14 to 0.42 mg
by Fusobacterium monensin/lb body
necrophorum and weight per day,
Arcanobacterium depending on the
pyogenes; for severity of the
prevention and coccidiosis
control of challenge, up to
coccidiosis caused 480 mg/head/day
by Eimeria bovis and 60 to 90 mg/
and E. zuernii; head/day tylosin
and for increased for the last 28 to
rate of weight 42 days on feed. A
gain and improved withdrawal time
feed efficiency in has not been
cattle fed in established for
confinement for pre-ruminating
slaughter for the calves. Do not use
last 28 to 42 days in calves to be
on feed. processed for
veal. See special
labeling
considerations in
Sec. Sec.
558.355(d) and
558.500(d) of this
chapter. Tylosin
provided by No.
016592 or 058198;
monensin as
provided by No.
016592 or 058198;
ractopamine
provided by No.
016592, 054771, or
058198 in Sec.
510.600(c) of this
chapter.
(xi) 8 to 10.................... Monensin 10 to 40 Cattle fed in Feed a minimum of 016592
plus ractopamine, confinement for 1.0 lb/head/day 054771
not to exceed 800. slaughter: For ractopamine Type C 058198
reduction of top dress feed
incidence of liver continuously to
abscesses caused cattle fed in
by Fusobacterium confinement for
necrophorum and slaughter, to
Arcanobacterium provide 70 to 400
pyogenes; for mg/head/day
prevention and ractopamine for
control of the last 28 to 42
coccidiosis caused days on feed. Feed
by Eimeria bovis on top of a ration
and E. zuernii; containing 10 to
and for increased 40 g/ton monensin
rate of weight and 8 to 10 g/ton
gain and improved tylosin phosphate,
feed efficiency in to provide 0.14 to
cattle fed in 0.42 mg monensin/
confinement for lb body weight/
slaughter for the day, depending on
last 28 to 42 days the severity of
on feed. the coccidiosis
challenge, up to
480 mg/head/day
and 60 to 90 mg/
head/day tylosin.
A withdrawal time
has not been
established for
pre-ruminating
calves. Do not use
in calves to be
processed for
veal. See special
labeling
considerations in
Sec. Sec.
558.355(d) and
558.500(d) of this
chapter. Tylosin
provided by No.
016592 or 058198;
monensin as
provided by No.
016592 or 058198;
ractopamine
provided by No.
016592, 054771, or
058198 in Sec.
510.600(c) of this
chapter.
[[Page 58016]]
(xii) 8 to 10................... Monensin 10 to 40 Cattle fed in Feed continuously 016592
plus ractopamine confinement for as sole ration to 054771
9.8 to 24.6. slaughter: For provide 90 to 430 058198
reduction of mg/head/day
incidence of liver ractopamine and
abscesses caused 0.14 to 0.42 mg
by Fusobacterium monensin/lb body
necrophorum and weight per day,
Arcanobacterium depending on the
pyogenes; for severity of the
prevention and coccidiosis
control of challenge, up to
coccidiosis caused 480 mg/head/day
by Eimeria bovis and 60 to 90 mg/
and E. zuernii; head/day tylosin
and for increased for the last 28 to
rate of weight 42 days on feed. A
gain, improved withdrawal time
feed efficiency, has not been
and increased established for
carcass leanness pre-ruminating
in cattle fed in calves. Do not use
confinement for in calves to be
slaughter for the processed for
last 28 to 42 days veal. See special
on feed. labeling
considerations in
Sec. Sec.
558.355(d) and
558.500(d) of this
chapter. Tylosin
as provided by No.
016592 or 058198;
monensin as
provided by No.
016592 or 058198;
ractopamine as
provided by No.
016592, 054771, or
058198 in Sec.
510.600(c) of this
chapter.
(xiii) 8 to 10.................. Monensin, 10 to 40 Heifers fed in Feed continuously 016592
plus ractopamine, confinement for as sole ration to 054771
9.8 to 24.6, plus slaughter: For provide 90 to 430 058198
melengestrol, reduction of mg/head/day
0.125 to 1 mg/lb. incidence of liver ractopamine and
abscesses caused 0.14 to 0.42 mg
by Fusobacterium monensin/lb body
necrophorum and weight per day,
Arcanobacterium depending on the
pyogenes; for severity of the
prevention and coccidiosis
control of challenge, up to
coccidiosis caused 480 mg/head/day
by Eimeria bovis and 60 to 90 mg/
and E. zuernii; head/day tylosin
for increased rate for the last 28 to
of weight gain, 42 days on feed.
improved feed Feed melengestrol
efficiency, and as a top dress or
increased carcass mixed with a
leanness; and complete ration at
suppression of the rate of 0.5 to
estrus (heat) in 2.0 pound/head/day
heifers fed in (specify one
confinement for level) to provide
slaughter for the 0.25 to 0.5 mg
last 28 to 42 days melengestrol
on feed. acetate/head/day
(specify one
level). A
withdrawal time
has not been
established for
pre-ruminating
calves. Do not use
in calves to be
processed for
veal. See special
labeling
considerations in
Sec. Sec.
558.342(d),
558.355(d), and
558.500(d) of this
chapter. Tylosin
provided by No.
016592 or 058198;
monensin as
provided by No.
016592 or 058198;
ractopamine as
provided by No.
016592, 054771, or
058198;
melengestrol
acetate as
provided by No.
016592 or 054771
in Sec.
510.600(c) of this
chapter.
* * * * * * *
----------------------------------------------------------------------------------------------------------------
* * * * *
Dated: October 12, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-22604 Filed 10-19-21; 8:45 am]
BILLING CODE 4164-01-P